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toward Engineering Native-like Bone, Cartilage, and Osteochondral Grafts 
Sarindr Bhumiratana 
Medical complications caused by bone, cartilage, and osteochoondral defects present special 
challenges to tissue engineers. An ability to fabricate these tissues in vitro will eliminate clinical 
complications caused by current techniques used in graft reconstruction. These complications 
include long-term failure of synthetic grafts, inferior success of allografts, and complications 
from harvesting autografts. The successfully engineered grafts must exhibit biological and 
structural function similar to that of native tissue in order to withstand physiological conditions 
and integrate into surrounding tissues. In this dissertation, the ability to control tissue matrix 
assembly from a clinically relevant cell source, human mesenchymal stem cells, towards 
generating native-like tissue properties has been demonstrated. The investigational approach was 
crafted around three specific aims: controlling the matrix assembly of bone mineral (Aim 1), 
articular cartilage (Aim 2), and osteochondral tissue (Aim 3). As a result, the assembly of bone 
mineral structure was accomplished by regulating nucleation, mineral-binding protein deposition 
sites, and affinity for mineral binding. Native-like articular cartilage with physiologic form and 
function was created using a cell pellet compression technique, a process mimicking the native 
developmental mesenchymal cell condensation process. In addition, the key requirements to 
engineer osteochondral tissue with undifferentiated mesenchymal stem cells were established. A 
radically novel, imaging-compatible perfusion bioreactor was designed to enhance tissue 
integration and spatial regulation of supplements to direct stem cell differentiation into 
chondrogenic and osteogenic lineages and the formation of complete osteochondral constructs. 
Proof-of-concept experimentation was conducted in a large animal (pig) model of 
temporomandibular condyle reconstruction. Engineered bone demonstrated markedly better 
 regeneration and remodeling of the TMJ and its integration with the surrounding tissues (bone 
and muscle) compared to the implantation of acellular scaffolds. The tissue engineering 
approaches developed in this dissertation form a basis for promising therapeutic approaches for 
treating bone, cartilage, and osteochondral defects.  
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CLINICAL POTENTIAL OF BONE, CARTILAGE, AND OSTEOCHONDRAL TISSUE ENGINEERING 
Engineering of functional tissue grafts offers a promising alternative method for treating large 
defects and replacement of failing tissues. In order to produce a successful graft, engineers, 
scientists, and clinicians need to consider the clinical requirements of the defect, the structural 
and functional necessities at the time of implantation, the approach to providing integration with 
the host tissue, immediate survival and long-term function. These general requirements translate 
into the specific set of design considerations that are typically addressed in a highly 
interdisciplinary manner. In all cases, the design requirements need to take into account the 
biology of tissue development, repair and (if applicable) disease conditions, the implantation 
route, and the necessary properties of engineered tissue grafts. For instance, bone, cartilage, and 
osteochondral tissue have unique mechanical function, which must be adequately addressed. 
Successful tissue grafts should re-establish the cellular and mechanical function of the native 
tissue while matching the size and shape of the defect.  
Autologous grafts are considered to be a gold standard for bone, cartilage, and osteochondral 
reconstruction due to their bioactivity, mechanical competence, and immediate cellular function. 
Nevertheless, alternative methods would eliminate the following disadvantages with the 
implementation of autologous grafts: the restricted volume of the tissue available for harvest, 
donor site morbidity, the lack of precision in size and shape, and the unmatched structural and 
biomechanical properties of tissues harvested. Allografts and graft substitutes may fulfill some of 
these obstacles but lack sufficient tissue healing responses, which leads to failure. Mimicking 
physiologic form and function of engineered bone, cartilage, and osteochondral tissue are 
important criteria for graft success which would offer a promising alternative method for treating 
 2 
skeletal defects. This dissertation aimed to generate native-like bone, articular cartilage, and 
osteochondral tissue in vitro from human stem cells. 
HYPOTHESIS 
The proposed hypothesis is that mesenchymal stem cells (MSC), when differentiated, can 
assemble native-like bone, articular cartilage, and osteochondral tissues by emulating the 
physiologic tissue developmental process. Based on the progress in bone, cartilage, and 
osteochondral tissue engineering (Chapter III), this dissertation aims at engineering native-like 
bone, articular cartilage, and osteochondral structures from MSC by regulating bone and 
cartilage tissue matrix assembly.  
SPECIFIC AIMS 
Bone, cartilage, and osteochondral tissue engineering have tremendously progressed over the 
past decade; however, engineering clinically relevant grafts from human mesenchymal stem cells 
(hMSC) is still far from fruition. Understanding mechanisms and developmental processes of in 
vitro tissue formation are beneficial for developing techniques and culture systems to 
successfully engineer functional grafts. This dissertation aims at investigating and solving unmet 
challenges in regard to the formation of bone, cartilage, and osteochondral tissue from hMSC in 
vitro. The focus is on controlling tissue matrix assembly in vitro by controlling the local hMSC 
environment as well as innovating novel fabrication of functional tissue constructs. The 
dissertation is divided into three specific aims focused on the techniques to regulate and control 
the matrix assembly of (i) bone, (ii) articular cartilage, and (iii) osteochondral construct.   
 
Aim 1 Engineering mineral architecture by directing mineral deposition of hMSCs through 
chemical and structural features of scaffolds 
 3 
 
Bone mineral architecture defines bone strength, stiffness, and durability. Previous bone tissue 
engineering techniques focused on chemically or structurally stimulating hMSC osteogenic 
differentiation to enhance osteogenic expression and production of bone matrix. However, the 
matrix deposited by hMSC in previous studies did not form native-like structures. This motivates 
the studies in regulating deposition of bone mineral and protein matrix onto defined locations 
resulting in controlled bone structural formation. The approach was designed to mimic the 
mechanism to form mineralized collagen fibrils, the native bone building block. As a result, the 
bone mineral and protein matrix deposition could be modulated, resulting in engineered bone 
with native-like structure and enhancement in mechanical function. 
 
Aim 2 Engineering articular cartilage with integration to subchondral bone from hMSC using 
novel cell pellet compression technique 
Cartilage constructs were successfully engineered from young primary animal chondrocytes, but 
not from hMSCs. All previous studies of cartilage tissue engineering using hMSCs reported poor 
compressive stiffness due to inferior assembly of cartilage matrix. Based on the developmental 
process of mesenchymal cell condensation that leads to the formation of cartilage during normal 
development, we proposed a novel technique that is based on hMSC pellets interfaced with 
subchondral bone. This innovative method was optimized to successfully engineer, for the first 
time, articular cartilage with physiological mechanical properties. 
 
Aim 3 Determining the requirements of tissue engineering osteochondral grafts 
 4 
Controlling spatial bone and cartilage formation from a single cell source within a construct is a 
difficult task, which requires substantial regulation of growth factors and stimuli. Understanding 
the requirements of successfully generating osteochondral grafts from a single stem cell source 
would facilitate the translation of tissue engineering approaches. This aim investigated the 
importance of MSC predifferentiation, the use of soluble factors, and bioreactors in the 
formation of stratified cartilage/bone (osteochondral constructs). The results provide insight into 
the necessary criteria for designing systems to engineer complete osteochondral grafts from 
hMSC in vitro.  
 
A bioreactor was designed for culturing anatomically-shaped osteochondral grafts from a single 
cell source. This system allows spatial control of bone and cartilage development as well as the 
enhancement of osteochondral integration. The temporomandibular joint (TMJ) condyle was 
selected as a model for the bioreactor design due to its size, anatomical complexity, and clinical 
need. The pre-clinical proof of concept in a large animal model was conducted to determine the 
efficacy of both bioreactor and the tissue-engineered anatomical autologous bone graft in 
regenerating tissue. More importantly, the outcomes of this study point to the practicality and 
promise of employing tissue engineering technology for the production of personalized 





Bone and Cartilage Biology, Medical Complications, and Current Treatments 
Mimicking physiologic form and function of engineered bone, cartilage, and osteochondral 
tissue is important for graft success and represents the main focus of this dissertation. Nature 
builds and repairs tissue through a complex process involving multiple biochemical factors and 
various cellular players that precisely interact in a well-controlled environments. Each tissue type 
undergoes unique developmental steps, and as a result, exhibits unique tissue architecture and 
function. Advances in bone and cartilage biology have determined the fundamental direction 
towards engineering tissue structure in vitro. Furthermore, understanding medical complications 
and current treatment modalities is essential for determining the success of tissue engineered 
bone, cartilage, and osteochondral grafts. 
BONE BIOLOGY AND STRUCTURE 
Bone is a hard connective tissue that provides mechanical and metabolic functions vital to 
survival and health; these functions include supporting the body’s framework, supplying blood 
cells to the entire body, and maintaining mineral and fat reserves. Bone varies in geometry, 
cellularity, mechanical properties, and developmental pathways. Flat bone and the outer regions 
of long bone are comprised of compact (cortical) bone that contains ~80-90% mineralized tissue. 
This high density of mineralized tissue provides mechanical strength. The ends of long bone are 
made primarily of trabecular (cancellous) bone, which contains ~15-25% mineralized tissue. 
Compared to cancellous bone, cortical bone has a much higher compressive stiffness (12-20 GPa 
vs 0.2-0.8 GPa) and strength (100-230 MPa vs 2-12 MPa) [1]. The mechanical properties of bone 
generally depend on its structure and orientation. A successful bone graft should ideally match 
the physiologic structure and mechanics of native bone being replaced. Therefore, understanding 
 6 
bone developmental biology will help tissue engineers to apply basic scientific knowledge to the 
engineering of functional bone grafts. 
Bone development 
Bone formation begins within the first month of development through two different processes: 
intramembranous ossification and endochondral ossification. Intramembranous ossification leads 
to flat bone formation when fibrous membranes are replaced by bone tissue. Examples of flat 
bones include the cranium (skull), illium (pelvis), and rib cage. Intramembranous ossification 
involves direct differentiation of mesenchymal cells into pre-osteoblasts and osteoblasts [2], 
while endochondral ossification involves the replacement of cartilage by bone tissue to form 
long bone. The two processes result in distinctly different compositions and structures of the 
bone matrix [3], although recent studies have identified several shared molecular regulators [4]. 
In both processes, the major events in bone development are the formation and infiltration of 
vasculature and the differentiation of stem cells into bone-forming cells. The key angiogenic 
regulators include members of the fibroblast growth factor (FGF), insulin-like growth factor 
(IGF), transforming growth factor-β (TGF-β), and vascular endothelial growth factor (VEGF) 
families [5, 6]. In addition, factors which play essential roles in bone development include 
growth hormones such as Indian Hedgehog (Ihh) and parathyroid hormone related peptide 
(PTHrP) [7, 8], FGF-2 [9, 10], and TFG-β family cytokines [11-13], especially BMPs [14, 15]. 
Bone remodeling 
Bone remodeling is a continual, lifelong process that stimulates bone regeneration, maintenance, 
and homeostatsis [16]. Remodeling is the bone’s response to signals associated with bone 
growth, micro-damage and mechanical loading. In the process, existing bone is resorbed by 
osteoclasts and new bone tissue is formed by osteoblasts. Signaling pathways include the action 
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of several hormones, such as PTHrP and vitamin D, and cytokines such as BMPs, FGF, IGF, 
TGF-β, PDGF (in bone formation) and GM-CSF, ILs, and M-Csf (in bone resorption) [16-18]. 
Bone healing 
Unlike soft tissue, healing of bone does not lead to scar formation and, if the defect is below a 
critical size, results in the reestablishment of native bone anatomy and function. Fracture repair is 
usually complete by 6-8 weeks after the initial injury and is characterized by the inflammatory 
phase, reparative phase (which includes intramembranous ossification), chondrogenesis followed 
by endochondral ossification, and remodeling [19, 20]. Examples of growth factors and 
extracellular matrix proteins involved in bone repair processes include TGF-β, FGF (I and II), 
PDGF, BMP (2, 4, and 7), osteonectin, osteocalcin, and collagens [21]. 
BONE MEDICAL COMPLICATIONS AND TREATMENTS 
Due to the multiple functions of bone in locomotion, mechanical support, and physical protection 
of various organs and metabolism, bone injury can cause significant pain, discomfort, and 
physical disability. Treatment options most commonly utilize a graft, which is a routine option 
for conditions following tumor resections and large fractures. Bone fracture is commonly caused 
by accident, high force impact or stress, or trivial injuries resulting from osteoporosis. Some 
fractures can lead to serious complications such as non-union fracture where the fractured bone 
fails to heal, mal-union where the fractured bone heals in a deformed manner, and compartment 
syndrome that may result in amputation of the affected limb. Most fractures require immediate 
treatment by securing the fracture in place to facilitate self-healing. Surgically-implanted bone 
grafts can enhance healing by filling in the gap of a nonunion and thereby facilitate bone 
integration and regeneration. After implantation, the graft needs to biologically and functionally 
integrate with the existing skeletal system. The three most clinically used bone grafts are 
autografts, allografts, and grafts substitutes, with each having its own advantages and 
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disadvantages. The treatment of choice depends on the patient’s general condition and the 
specific fracture or symptom 
Autografts, which are grafts taken from the patient’s own skeletal system, represent the gold 
standard in bone grafting. The bone graft is harvested from non-essential bone such as the illiac 
crest and cut into the shape and size needed. Therefore, this method requires an additional 
surgical site and may introduce additional post-operative pain and complications. Furthermore, 
the size and total amount that can be harvested is limited. Despite these drawbacks, autografts 
are often preferred because they alleviate the risks of graft rejection and disease transmission. A 
special type of structural autograft is the vascularized fibular graft, which requires a 
microsurgical approach to connect the nutrient fibular vessel to a vascular bundle adjacent to the 
site of the defect. The operation causes high morbidity at the donor site, and its usage is 
generally limited to tumor reconstructions [22, 23]. 
Allografts are bone grafts harvested from human donors. Bone allografts include fresh or fresh-
frozen bone, freeze-dried bone grafts, and demineralized freeze-dried bone grafts. As compared 
to autografts, allografts offer a better supply of bone in suitable shapes and sizes, and help avoid 
the donor site morbidity. However, allografts pose a risk of immune rejection and infection since 
the tissue is harvested from another individual and contains foreign immunogenic material. 
These risks are reduced when the cellular materials are removed during the graft processing and 
storage, such as in decellularized and demineralized bone allografts.  
Graft substitutes include natural or synthetic materials, which can be organic, inorganic, or 
combinatorial products. Graft substitutes are available in unlimited supply, and can be fabricated 
in any desired size and shape. The materials used as graft substitutes include collagen sponge, 
calcium phosphates (e.g. hydroxyapatite and tricalcium phosphate), bioactive glass, and metals 
such as titanium and its alloys. These materials provide osteoconductivity for bone healing 
formation and some of them are resorbed with time in vivo. Graft substitutes provide less risk of 
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infection and graft immune rejection in comparison to allografts. However, stress shielding, 
which may cause bone atrophy, is a concern when applying this type of graft. Although graft 
substitutes offer great benefits, they are still inferior to autografts and allografts in terms of 
enhancing bone healing through biological response. 
CARTILAGE BIOLOGY AND STRUCTURE 
Articular cartilage, a white, dense connective tissue, serves as the load-bearing material of joints 
and is characterized by its excellent lubrication, and wear properties [24]. Ranging from 1 to 7 
mm thick, cartilage is composed primarily of two phases; a solid matrix (collagen fibrils and 
proteoglycan (PG) macromolecules) [25-27] and a mobile interstitial fluid phase (mostly water) 
[28, 29]. The polyanionic nature of the glycosaminoglycan (GAG) chains of PG draw water into 
the tissue [29], resulting in a large osmotic pressure that expands against the constraining 
collagen network. The interplay between swelling pressure and tension in the collagen fibers 
results in a highly specialized tissue that is well suited to bear compressive loads within the joint. 
To maintain the necessary matrix composition, chondrocytes, which make up less than 10% of 
the tissue volume [30], balance extracellular degradation and matrix turnover by synthesizing 
and secreting extracellular matrix (ECM).  
The composition, structure, and material properties of articular cartilage are known to vary 
across the tissue’s depth [31] and can be divided into four discrete zones: the superficial, middle, 
deep, and calcified cartilage zones [32, 33]. The superficial zone is a thin region at the 
articulating surface marked by collagen fibers that have the highest concentrations of water and 
collagen compared to the other zones, but the lowest level of proteoglycans. Additionally, 
chondrocytes in this zone are flattened. In contrast, the middle zone is rich in randomly oriented 
collagen, contains the highest concentration of proteoglycans, and is randomly dispersed with 
cellular bodies. In the deep zone, which has the lowest levels of collagen, the chondrocytes are 
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oriented perpendicularly to the surface and arranged in a columnar structure. Finally, the 
calcified cartilage zone separates the uncalcified layers of cartilage from the subchondral bone.   
CARTILAGE MEDICAL COMPLICATIONS AND TREATMENTS 
In most cases, damage to articular cartilage is a consequence of clinical osteoarthritis and is 
marked by disability and pain [34]. Affecting nine percent of the United States population aged 
30 and older, osteoarthritis has total direct costs estimated at $28.6 billion dollars annually [35]. 
Due to its avascular nature, articular cartilage exhibits a poor intrinsic healing response [36]. The 
hallmarks of this debilitating disease are the loss of mechanical properties, increased collagen 
degradation, reduced proteoglycan synthesis, and decreased cellularity [37, 38].  
Alternatively, damage to cartilage can be caused by physical injury of the articular surface. 
While physical injury to cartilage primarily occurs with traumatic loading of the joint (traumatic 
injury), it can also be a consequence of surgical procedures that include graft harvesting 
(iatrogenic injury). In native cartilage, the mechanotransduction resulting from injury can induce 
chondrocyte death as early as within a few hours, and up to 7 days post-injury [39]. The 
subsequent downstream effects are frequently marked by changes similar to those seen in 
osteoarthritis.  
When damage to the tissue is widespread, a total joint replacement is often the only solution, 
artificially replacing the articulating surface and underlying bone. Such invasive repairs, 
however, often require revision surgeries due to wear, subsidence and loosening of the implant in 
the bony union [40-43]. For the repair of focal lesions and damage to the articular surface, more 
conservative approaches may be used. Clinical options include tissue adhesives [44, 45], 
enzymatic treatments [46], laser solder welding [47], autograft cell/tissue transfer via periosteal 
grafts [48], autologous osteochondral grafting such as mosaicplasty [49] or costcochondral graft 
[50, 51] and the Carticel method [52]. While these options offer temporary relief of symptoms, 
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they also introduce long-term problems. Primarily, the availability of healthy cartilage from 
which to harvest cells is limited for cell-based therapies or osteochondral graft harvesting. 
Furthermore, autologous osteochondral grafts are usually harvested from non-load bearing 
regions which may provide tissue of sub-optimal material properties for use in contact regions 
[53]. This procedure itself can induce significant cell death in the surrounding region [54, 55], 




Progress in Bone, Cartilage, and Osteochondral Tissue Engineering 
An “ideal” process for engineering functional bone, cartilage, and osteochondral grafts that 
would be tailored to a patient’s and specific defect is illustrated (Fig.III) The personalization of 
tailored grafts provides an exact match to the defects being reconstructed. The process utilizes 
computer-assisted imaging and preoperative planning to guide manufacturing of patient-specific 
implants. Using a computer program, the 3-dimensional contour, size, and shape of the graft is 
designed, and the anatomically shaped scaffold is fabricated. Cells are then seeded into the 
scaffold and cultured in a specially designed “anatomical” bioreactor to support the development 
of engineered bone grafts.  The graft is then implanted into the patient and allowed to integrate 
with the native tissue. The personalizing process and the capability of creating anatomical and 
functional tissue grafts would greatly facilitate the surgical procedure as well as improve the 
aesthetics of bone repair. Successful tissue engineering of functional bone, cartilage, and 
osteochondral grafts requires specific and careful consideration of the three major players of 
tissue engineering: cells, scaffolds, and environmental factors provided by the bioreactor.  
CELL SOURCE 
Cells play an important role in bone, cartilage, and osteochondral tissue engineering by forming 
and remodeling the tissue-specific extracellular matrix. Primary cells extracted from adult tissue 
(osteoblasts and chondrocytes in this case) have been used extensively to validate the feasibility 
of tissue engineering approaches because these cells exhibit native cellular functions. Primary 
osteoblasts and chondrocytes harvested from bone and cartilage, respectively, maintain genetic 
expression and produce tissue matrix similar to that found in the native tissue when cultured in 
vitro [56-60]. However, these cells are not clinically favorable due to the complications 
associated with their harvest and expansion: these include donor site morbidity, the difficulty of 
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Figure III: Engineering of cartilage/bone grafts. The process begins with 3D imaging of the 
defects for manufacturing an anatomically-shaped scaffold consisting of strong mineralized 
region for the formation of bone, and hydrogel region for the formation of cartilage. Both regions 
are seeded with cells and cultured in a bioreactor (also manufactured with the aid of imaging) 
that provides environmental control and physical stimulation. After cultivation, the functional 
graft can be implanted at the defect site. 
Adult stem cells, particularly mesenchymal stem cells (MSCs), have demonstrated high clinical 
potential for bone, cartilage, and osteochondral tissue engineering. Although these cells also 
need to be harvested from the body, the process is much less invasive and much simpler than 
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obtaining primary cells. Bone marrow mesenchymal stem cells (BMSCs) and adipose-derived 
mesenchymal stem cells (ASCs) can simply be isolated from aspirates of bone marrow and fat, 
respectively. BMSCs are the most extensively investigated and utilized therapeutic cells for 
orthopedic regeneration and reconstructive therapies [30]. ASCs have similar immunophenotype, 
morphology, and multilineage potential to BMSCs. Because ASCs are more abundant and more 
accessible than BMSCs, causing very little donor site morbidity, these cells are being actively 
investigated as an alternative to BMSCs [61, 62]. 
Other MSC sources which are less investigated yet potentially beneficial include dental pulp 
stem cells (DPSCs) and umbilical cord-derived stem cells (UCSCs). DPSCs can be extracted 
from dental pulp at the time of tooth extraction [63]. Harvesting UCSCs is also not invasive, 
however, they must be isolated and stored at birth limiting potential clinical use for a large 
fraction of the current population [64]. Similar to BMSCs and ASCs, DPSCs can be 
differentiated into osteoblasts which are able to form mineralized bone tissue in vitro [65]. 
UCSCs also exhibit potential for orthopeadic cell-based therapy with even greater proliferative 
capability than BMSCs [64]. Tissue engineering processes to generate bone grafts require 
isolation, purification, and in vitro expansion in order to obtain adequate numbers of high-quality 
cells. The ease of isolation, in vitro proliferative capability, and pluripotency make stem cells 
suitable for therapeutic purposes and a more attractive cell source than primary cells. 
Despite the pluripotency of embryonic and fetal stem cells, these cell sources have not yet shown 
advantages over adult stem cells in tissue forming capability. Futher, they are not autologous, 
and related ethical controversies persist. Nevertheless, the technique of manipulating embryonic 
stem cells for engineering bone has been established and has demonstrated success in bone 
formation both in vitro and in vivo [66]. 
Human induced pluripotent stem cells (iPSC) offer the potential for engineering a wide range of 
tissues, as these cells are both autologous and pluripotent [67]. Osteogenic potential of iPSC has 
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been demonstrated through direct differentiation and derivation of MSC-like cells [68]. 
However, the clinical applicability of iPSC is still far from fruition. iPSCs evolve very slowly in 
culture, and yields can be rather low [67]. In addition, the iPSC used for therapeutic purposes 
must be free of genomic insertions of transgene sequences [68]. Novel techniques must be 
developed to overcome these obstacles prior to clinical use.  
To date, adult MSCs have demonstrated the highest clinical potential in the application of bone, 
cartilage, and osteochondral tissue engineering; therefore, this cell source was selected for the 
present studies. In order to successfully form osteochondral tissue in vitro, suitable scaffolds and 
environmental factors must be applied to direct adult MSCs differentiation. The cells must 
develop into osteogenic and chondrogenic lineages and assemble tissues at the defined locations 
i.e. form bone in the subchondral bone region and cartilage matrix in the articular surface region. 
In addition, the structure and quality of the tissue formed should match the native tissue for 
functional purposes. Numerous efforts have been attempted to engineer bone, cartilage, and 
osteochondral tissue, with current approaches reviewed below. 
BONE TISSUE ENGINEERING 
A successful bone graft should ideally match the physiological properties of the implant location 
in addition to providing a platform for healing. Scaffolds used in bone tissue engineering need to 
resemble the extracellular matrix of bone tissue, and thereby provide infrastructure for the cells 
to reside, proliferate, differentiate, and assemble mechanically functional bone [69]. In addition, 
scaffolds should be biocompatible, degradable into non-toxic products, osteoconductive (to 
recruit bone cells from the recipient), osteoinductive (to differentiate stem cells into bone-
forming cells), osteointegrative (to provide permanent and functional attachment to native bone), 
and exhibit mechanical properties similar to those of native bone. Scaffolds composed of natural 
substances, protein- or organic-based polymers, ceramics, metals, as well as their combinations, 
have been extensively investigated for application in bone tissue engineering. Each material has 
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advantages and disadvantages. For example, organic polymers such as silk and poly-lactic-
glycolic acid are much less stiff than native bone, and are easily fabricated into desired size, 
shape and porosity [70, 71]. In contrast, ceramics such as hydroxyapatite have mechanical 
properties similar to native bone but has limited structural flexibility [72, 73]. Optimization of 
materials for bone tissue engineering is still in progress [74-76]. 
Engineering clinically-sized autologous bone grafts requires the availability of large numbers of 
cells and advanced cultivation systems for seeding and cultivation of anatomically shaped 
scaffolds, sufficient nutrient delivery to the cells within scaffolds, and regulatory signals for cell 
differentiation and functional assembly [77]. In a suitable environment and with adequate 
stimulation, MSCs differentiate into osteogenic cells, and produce bone proteins and minerals 
[78, 79]. Biological and chemical factors such as dexamethasone [80] and BMP-2 [81, 82] have 
been shown to play significant roles in stimulating MSC osteogenic differentiation.  
Mechanical signaling is also essential for bone formation. Physiologically, two types of 
mechanical cues that can affect bone formation are mechanical compression and shear stress 
[83]. Various technologies have been developed for engineering human bone grafts by utilizing 
scaffolds and bioreactors [77, 84, 85]. Specially designed bioreactors have been used, including 
spinner flasks, rotating wall vessels, and perfusion bioreactors [86-88] to maintain cell viability 
and achieve homogenous tissue development inside large constructs. Perfusion bioreactors have 
exhibited the most promising results in terms of controllability and bone tissue formation.  
A typical bone bioreactor with medium perfusion consists of a medium reservoir, a culture 
chamber, and a perfusion loop with a pump and gas exchanger. The pump draws media from the 
reservoir through the cell-seeded scaffold, which resides in the culture chamber. Medium flow 
serves two purposes: provision of convective nutrient supply to the cells inside the porous 
construct, and mechanical stimulation through fluid shear load. Tissue engineered bones via 
perfusion bioreactors have been shown to be superior over those engineered by static culture [89] 
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and spinner flasks [90]. The effect of fluid shear stress enhances progressive deposition of 
mineralized matrix throughout the 3D engineered tissue constructs [79]. Perfusion bioreactors 
have shown an enhancement of bone-like tissue development in terms of production of bone 
matrix, (i.e., collagen type I, osteocalcin, osteopontin, and bone sialoprotein) in hMSC-seeded 
decellularized bovine trabecular bone [87]. Cellular content similar to native bone was achieved 
under optimal conditions in perfusion bioreactors [78]. More importantly, tissue engineered bone 
grafts were superior to either scaffold alone or cell-seeded scaffold in terms of graft 
incorporation into the critical size mouse calvarial bone defects [91]. 
CARTILAGE TISSUE ENGINEERING 
Successfully engineered cartilage must mimic native-like tissue mechanics as well as cellular 
activity. Hydrogels have become the scaffold material of choice for cartilage tissue engineering 
due to their intrinsic hydrophilic nature and high water content, which similar to native soft 
hydrated tissues [92]. Investigated hydrogels include polyethylene(glycol) [93], hyaluronic acid 
[94], silk [95], collagen [96], and agarose [97-103]. 
Chondrocyte-seeded agarose constructs have been shown to successfully repair articular cartilage 
and tibial defects in animal models [104, 105]. The properties of agarose permit application of 
physiologic deformational loading immediately upon encapsulation such that constructs may be 
physically stimulated before extensive ECM development. Together, the characteristics of the 
agarose hydrogel system have allowed for the fabrication of the most reproducible and robust 
cartilage tissue growth in culture [106]. Furthermore, this system serves as an important tool to 
study tissue-engineering strategies. Clinically, agarose is being used as a co-polymer with 
alginate as a hydrogel scaffold for a commercial product, ACI (Cartipatch), used in cartilage 
defect repair and has demonstrated good 2-year clinical follow up [107, 108]. 
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Focused efforts on applying a range of chemical cues such as growth factors (transforming 
growth factor (TGF)-β3, TGF-β1, insulin-like growth factor (IGF), fibroblast growth factor 
(FGF2) [109-112]), corticosteroids [113, 114], and interleukins [115-117] have been investigated. 
Through paracrine signaling and direct cell-cell contact, the exchange of these chemical factors 
promotes extracellular matrix development. For functional tissue engineering, physiologically 
relevant stimuli were applied to encourage the development in vitro [118]. Rotating wall 
bioreactors have been used to provide a hydrodynamic, low-shear environment supportive of 
enhanced nutrient transport [119, 120] and cartilage-like tissue growth [121-123]. However, 
these bioreactors do not reproduce the physiologic deformational loading and hydrostatic 
pressure environment of the chondrocyte [124]. In comparison, applying physiologic loading 
through a combination of applied physiologic hydrostatic pressure and perfusion [125] or 
dynamic deformation loading [59, 102, 103] can achieve near-physiologic values for equilibrium 
modulus and GAG content. Applied deformational loading gives rise to enhanced convection of 
nutrients [126, 127], in a mechanism similar to how joint loading provides nutrients from the 
synovial fluid to avascular cartilage in situ. There is a growing body of literature suggesting that 
physical forces can be used to modulate chondrogenesis of MSCs [128-131], as reviewed by 
Huang and co-workers [132]. However, to date, tissue engineered cartilage from MSCs has not 
yet accomplished similar tissue quality as tissue engineered cartilage from primary chondrocytes. 
OSTEOCHONDRAL TISSUE ENGINEERING 
Osteochondral tissue engineering focuses on forming cartilage and bone in a spatially controlled 
manner i.e. bone formation in the subchondral region and cartilage formation on the articular 
surface. Strong integration between the two tissues is a neccessity for successful, tissue 
engineered osteochondral grafts. Integration can be attained by suturing, cell-mediated ECM 
formation, and the use of fibrin and other glues [133]. Since differentiating MSCs into 
osteogenic and chondrogenic lineages require different stimulating factors (i.e. organic 
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phosphate for osteogenic induction and TGF-β3 for chondrogenic induction), engineering fully 
developed osteochondral constructs in vitro is challenging. One strategy to spatially control stem 
cell differentiation is to pre-induce stem cells to develop into specific lineages prior to 
fabrication of the osteochondral constructs. MSCs were pre-differentiated with chondrogenic and 
osteogenic factors in 2D and 3D, prior to combining them into osteochondral constructs [134-
136]. However, the constructs fabricated utilizing this system did not show strong integration or 
native-like bone and cartilage structure. 
SUMMARY 
Bone, cartilage, and osteochondral tissue engineering have progressed significantly. Successful 
development of these engineered tissues must exhibit biological factors and structures similar to 
native tissues to provide proper support and function. hMSC are the most clinically relevant cell 
source due to their proliferative capability and their ability to differentiate into osteogenic and 
chondrogenic lineages; thus, this cell source was selected for all of the studies conducted in this 
dissertation. The ability to control hMSC differentiation with cultivation media and growth 
factors allows for tissue development into specific lineages. However, there is a limited number 
of hMSC approaches which demonstrate the ability to control native-like tissue structure 
formation. This dissertation focuses on systems providing native-like control of the development 




Goals, Rationale, and Investigational Approach 
GOALS 
The goal of this dissertation is to regulate in vitro development of bone, articular cartilage, and 
osteochondral tissue from hMSC into constructs with native structural and mechanical 
properties. hMSC demonstrates the potential of differentiation into bone and cartilage; however, 
controlling the tissue architecture formed with hMSC has not been successful. The difficulty in 
regulating tissue matrix assembly and the lack of techniques to spatially control hMSC 
differentiation and direct matrix deposition into native-like structures have been the major 
stumbling blocks to successful hMSC graft formation. The proposed hypothesis is that the 
control of hMSC differentiation in a manner consistent with physiological development can 
result in the in vitro assembly of native-like bone, cartilage, and osteochondral tissues. 
The overall investigational approach was to apply physiologic tissue developmental processes 
towards the formation of native-like bone, cartilage, and osteochondral structures. The technique 
of engineering tissue from hMSC in vitro provides insights into the development of systems for 
the engineering of implantable, personalized, and functional tissue grafts. Various tissue-
engineering techniques including the design of novel scaffolds and bioreactors and the 
manipulation of tissue fabrication process have been employed to study the hypothesis. The 
research in this dissertation was divided into three coordinated aims: (i) regulate bone mineral 
matrix assembly (Aim 1), (ii) govern articular cartilage development (Aim 2), and (iii) spatially 




AIM 1: ENGINEERING MINERAL ARCHITECTURE BY DIRECTING hMSC MINERAL DEPOSITION 
THROUGH SCAFFOLD FEATURES 
Introduction to the Problem 
There have been numerous efforts to enhance and improve tissue engineered bone formation 
from hMSCs. hMSCs were osteogenicly induced through combinations of scaffold properties 
and chemical compositions, media supplements, and mechanical stimulations provided by 
bioreactors. The osteogenic differentiation of hMSCs is a suitable indication of successful tissue 
engineered bone formation. However, the genetic expression and the matrix production provided 
by the differentiated hMSC have not been translatable. Inside tissue-engineered bones, the entire 
tissue does not exhibit the form and function of native bone, and instead shows particulate 
mineral formation within the pore space of the scaffold rather than the connective mineral 
architecture seen in native bone [137, 138]. As a result, mechanical properties of the tissue 
engineered bone were significantly inferior to native bone, as the structure and architecture of 
bone matrix comprise bone strength and stiffness [139]. This aim investigated the mineralization 
process of tissue-engineered bone in vitro and control of the localization of deposited minerals. 
Topic Background 
A thorough understanding of native bone biology and the developmental process facilitates an 
experimental design to regulate formation of bone mineral architecture. The basic building 
blocks of bone are the mineralized collagen fibrils. The collagen constitutes the main component 
of a three-dimensional matrix in which the mineral forms. The mineral in this family of materials 
is dahllite, also known as carbonated apatite (Ca5(PO4, CO3)3(OH)) [140]. The major components 
are intimately associated into an ordered structure of mineralized collagen fibrils. The manner in 
which the building blocks are organized into higher order structures can also vary, and in fact, is 
the basis for differentiating between different types of bone such as cancellous, cortical, 
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mineralized tendon, and teeth. Seven levels of hierarchical organization of the family of 
mineralized collagen based materials were categorized ranging from nanoscale (mineral crystal) 
to macroscopic level (bone) [141]. As a result, this unique architecture of the bone contributes to 
its superior strength and toughness in comparison to synthetic materials. 
Mineralization signaling molecules 
Many organic and inorganic molecules play essential roles in bone mineralization. In addition to 
calcium, phosphate, and collagen, which are the components of bone mineral, many other 
important molecules play various roles in stimulating, and controlling mineral formation. 
Selected molecules are described in greater detail as follows. 
Alkaline Phosphatase (ALP): During tissue mineralization, osteoblasts significantly increase the 
production of ALP  which in turn cleaves phosphate esters to produce free inorganic phosphate. 
In addition to being the main component of hydroxyapatite, inorganic phosphate also acts as a 
signaling molecule and effects gene expression. Inorganic phosphate has been shown to induce 
the expression of several mineralization-involved proteins [142]. In addition, elevation of 
inorganic phosphate results in the upregulation of type II and III sodium-dependent phosphate 
transporters. These transporters facilitate the influx of inorganic phosphate into the cell, resulting 
in further induction of genes, including ALP [143, 144]. 
Pyrophosphate (PPi): PPi (P2O74-) is formed by the hydrolysis of ATP into AMP in cells. It has 
been shown that PPi inhibits mineralization in three ways: (i) It can prevent mineral growth by 
binding to the outer surface of the mineral; (ii) it induces the expression of osteopontin; and (iii) 
although PPi itself is a substrate for ALP, it can prevent the cleavage of the phosphate esters by 
inhibition of ALP in an uncompetitive way. However, PPi can also be cleaved by ALP into 
inorganic phosphate to facilitate mineral formation. 
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Non-collagenous proteins (NCPs): Bone mineralization is regulated by several extracellular 
proteins found in the organic matrix of bone [145-147], including a group of small integrin 
binding ligand N-linked glycoproteins (SIBLING) such as bone sialoprotein (BSP), and 
osteopontin (OPN). These proteins share some common features such as multiple 
phosphorylation sites, the possession of an Arg-Gly-Asp integrin binding motif and a highly 
acidic nature. Due to their integrin binding properties, these molecules can bind to the plasma 
membrane and are involved in signaling events between the cell and the ECM. 
Bone sialoprotein is expressed nearly exclusively in mineralizing tissue [148]. It can specifically 
bind to collagen via a 20 AA long domain. Furthermore, BSP can bind hydroxyapatite through 
two glutamic acid-rich regions, which are both required for its functional activity as a nucleator 
of hydroxyapatite [149]. In addition, it has been demonstrated that after treatment with 
organophosphate for 4 – 8 h, bone sialoprotein localizes to the ECM in osteoblastic cultures, well 
before the first appearance of apatite crystals [150, 151]. This suggests that inorganic phosphate 
triggers BSP into the extracellular matrix where it can subsequently nucleate calcium phosphate 
in metastable solutions. 
It has been reported that another specific bone matrix protein, bone acidic glycoprotein-75 
(BAG-75), predicts the location of mineral nucleation, and possibly recruits bone sialoprotein 
[145, 152]. Purified BAG-75 can self-associate into supramolecular spherical complexes and 
sequester millimolar quantities of inorganic phosphate These properties indicate that BAG-75 
generates a localized inorganic phosphate source for crystal nucleation reactions [153]. 
Interestingly, it has been proposed that bone sialoprotein is associated with a population of 
vesicle-like structures (defined as crystal ghosts), which are 500 – 800 nm in size. Bone 
sialoprotein does not, however, associate with the smaller 50 – 300 nm vesicle population [145]. 
Osteopontin is a protein with a wide distribution. It is found in mineralized tissues, in epithelial 
lining cells of numerous organs, and in body fluids. Many functions have been attributed to 
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osteopontin, including inhibition of bone mineralization and of pathologic calcification [154]. 
The effect of osteopontin on mineralization is dependent on its phosphorylation level, as 
dephosphorylated osteopontin does not inhibit mineralization while highly phosphorylated 
osteopontin promotes mineralization [155, 156]. On the other hand, osteopontin tends to be 
enriched on surfaces undergoing bone turnover and regulates adhesion and activity of 
osteoclasts, facilitating osteoclastic bone resorption [157]. 
In addition to the SIBLING protein family, a number of other proteins have been identified to be 
involved with and/or regulate matrix mineralization. These include acidic proteins such as 
osteocalcin, and SPARC (secreted protein, acidic, rich in cysteine) also known as osteonectin. 
Osteocalcin is the most abundant osteoblast-specific noncollagenous protein [158]. Osteocalcin 
binds to hydroxyapatite by means of its g-carboxyglutamic acid-rich region, and its synthesis and 
accumulation in bone is highly correlated to mineral deposition. Osteocalcin-null mice develop a 
phenotype that is marked by a higher bone mass without a change in osteoblast number, although 
osteoclast number is doubled. These mice do not respond to ovariectomy, indicating that bone 
resorption is not impaired [158]. Osteocalcin is proposed to play a role in remodeling as 
osteocalcin implants stimulate bone formation, osteoclast activity and early onset for remodeling 
[159], demonstrated by osteocalcin-null mice which are impaired in resorbing bone particles 
[73].  
Osteonectin is a calcium-binding glycoprotein found bound to type I collagen in many tissues 
undergoing remodeling [154]. Osteonectin-null mice display a decreased bone formation and 
osteoblast and osteoclast number, resulting in a decreased bone remodeling which causes a 
profound osteopenia, indicating that osteonectin might also play a role in cell differentiation. 
Furthermore, several in-vitro studies have demonstrated that osteonectin can prevent crystal 
nucleation and retard crystal growth [160]. 
 25 
Cell-mediated mineralization 
Mineralization may occur through osteoblast-driven or chondrocyte-driven ossification. 
However, due to the scope of this study on bone mineralization with osteogenic induced MSCs 
in a tissue-engineering model, only osteoblast-driven ossification is discussed. Osteoblasts 
express a number of genes that code for bone matrix components and enzymes that are involved 
in bone synthesis, including type I collagen, tissue non-specific alkaline phosphatase (ALP), 
bone sialoprotein, osteocalcin and osteopontin. Many of these genes are under the control of the 
osteoblast-specific transcription factor Runx2. As the bone matrix continues to grow, the 
osteoblasts get entrapped in their own matrix and terminally differentiate into osteocytes or 
undergo apoptosis. 
Understanding detailed mineralizing mechanisms is essential for the application of engineering 
bone architecture with hMSCs. Bone mineralization occurs based on two mechanisms: (i) a 
spontaneous mineral precipitation; and (ii) an infiltration of amorphous calcium phosphate 
complex, which may intertwine (Fig.IV-1). Mineralization is subject to spontaneous 
precipitation from concentrated calcium and phosphate ions initiated at the site of non-
collagenous proteins (NCPs). A study demonstrated that spontaneous hydroxyapatite crystal 
precipitation occurs with the presence of bone sialoprotein but not in the presence of osteopontin 
[161]. Following the initiation, the crystal then nucleates to form rigid mineral structure. To 
induce cell-mediated mineralization, the organism has to create an environment in which the 
metastable equilibrium between Ca2+ and PO43- is disturbed, leading to precipitation of Cax(PO4)y 
complexes. Disturbance of the equilibrium can be achieved by a local increase of calcium and/or 
inorganic phosphate, or an alteration of the molecules that inhibit or facilitate precipitation of the 
two ions. Physiologically, an increase in phosphate concentration is a common event in 
mineralization and can be found in the hypertrophic zone of the growth plate and under the 
mineral facing surfaces of osteoblasts [142] and odontoblasts [143].  
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Figure IV-1: Mechanism of cell-mediated bone mineralization. In osteoblast/osteocytes 
matrix extracellular phosphoglycoprotein (MEPE) negatively regulates the phosphate 
concentration via FGF23 and phosphate-regulating gene with homologies to endopeptidases on 
X-chromosome (PHEX). Increasing inorganic phosphate stimulates the expression of a number 
of proteins, such as bone sialoprotein and SPARC (secreted protein, acidic, rich in cysteine). 
These proteins initiate mineralization around type I collagen fibers by binding of calcium and 
inorganic phosphate. Propagation of mineralization is negatively regulated by phosphorylated 
osteopontin and dentin matrix protein 1 (DMP1), which may be reversed by TNAP, or cleavage 
by PHEX. Several membrane enclosed structures (lower panel, bottom half) have been related to 
mineralization. (a) Formation of intracellular vacuoles containing mineral needles (or empty 
ghosts), which are excreted into the extracellular matrix (ECM). Bone acidic glycoprotein-75 
(BAG-75) sequesters high quantities of inorganic phosphate and recruits bone sialoprotein to 
these structures, enabling further mineralization. (b) Multilamellar vesicles are found in vascular 
smooth muscle cell (VSMC)-mineralization, and (c) matrix vesicles are present in all forms of 
mineralization. (d) Exosomes are excreted during osteoblast- mediated mineralization. (e) These 
structures may associate with collagen fibers and facilitate mineralization, resulting in 
mineralized collagen fibers cover with lipid vesicles [162]. 
Another major theory of cell-mediated mineralization of bone proposes that mineralization is 
initiated by an intracellular origin. Rohde et al. described a novel model for mineralization by 
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osteoblasts, in which amorphous calcium/phosphate material is directly secreted via an 
exocytotic process from vacuoles of the osteoblast [163]. Many studies have demonstrated the 
presence of intracellular mineral structures inside vesicles of an osteoblastic cell [145, 150, 152]. 
TEM micrographs of mineralized nodules formed by osteoblasts after 28 days in culture showed 
matrix vesicle containing needle-like apatite crystals inside a cell [164]. In addition, BMP-2 
stimulated bone marrow-derived mesenchymal stem cells develop needle-like amorphous 
calcium/phosphate (ACP) structures inside vacuoles [163]. These mineralization needles consist 
of two different phases: a mineral-containing phase and a white, hollow, presumably 
proteinaceous phase. It was hypothesized that the deposited crystals propagated into the collagen 
fibril matrix after excretion, and once there, matured to hydroxyapatite.  
In vitro collagen mineralization was achieved by substituting the NCPs either with polyaspartic 
acid (pASP) or with fetuin, both inhibitors of hydroxyapatite crystallization [165, 166]. By 
employing such technique, the detailed mechanism of mineralization of collagen fibrils was 
recently developed [167]. The study proposed pre-nucleation calcium phosphate clusters form 
complexes with the functional matrix (in this case pASP) resulting in negatively charged, loosely 
packed, diffusive structures. The exact structure and composition of the pre-nucleation clusters 
are unknown at this time. Collagen fibrils, which contain positively charged regions at the border 
of the gap and overlap zones (close to the C-terminal), allow for pre-nucleation calcium 
phosphate infiltration. Pre-nucleation clusters infiltrate the nano-sized, positively charged region 
and bind to a distinct region on the collagen fibers. Once inside the collagen, the fluid diffuses 
through the interior of the fibril, solidifies into a disordered amorphous phase and, finally, 
becomes oriented crystalline hydroxyapatite inside the fibrils (Fig.IV-2).  
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Figure IV-2: Mineralization of a collagen fibril. a, Calcium phosphate clusters (green) form 
complexes with the polymer (orange line), forming stable mineral droplets. b, Mineral droplets 
bind to a distinct region on the collagen fibres and enter the fibril. c, Once inside the collagen, 
the mineral in a liquid state diffuses through the interior of the fibril and solidifies into a 
disordered (amorphous) phase (black). d, Finally, directed by the collagen, the amorphous 
mineral transforms into oriented apatite crystals (yellow) [168]. 
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Development of Theory and Hypothesis 
In order to induce formation of bone architecture in vitro, it is critical to control the locale for 
mineral deposition. As mentioned earlier, the two mechanisms of bone mineralization currently 
accepted are spontaneous precipitation and formation of NCP-mineral complexes. Mineral 
precipitation is initiated at the site of NCPs or nucleated to form a larger structure. In contrast, 
the NCP-mineral complex infiltrates collagen fibrils or deposits on scaffolding platform. This 
aim focuses on controlling mineral deposition from hMSCs based on the two known 
mineralization mechanisms. hMSCs, once osteogenicly induced, produces bone matrix proteins 
such as collagen type I and NCPs, and deposit mineral through alteration of the 
calcium/phosphate environments and deposition of ACP. The strategy for engineering bone 
architecture is to direct mineral deposition and absorption onto the designed structure. Three 
distinct strategies to investigate and control in vitro mineralization were developed and 
investigated. 
Aim 1.1: Nucleation and growth of mineralized bone matrix on silk-hydroxyapatite composite 
scaffolds (Chapter V) 
This aim is motivated by the concept that bone mineral nucleates from pre-existing mineral. In 
addition, our preliminary data suggested that in the conventional tissue engineered bone 
cultivation method, hMSCs cannot produce sufficient mineral to match that of the native bone 
within 5 weeks of culture. We hypothesized that pre-existing minerals embedded in a silk sponge 
scaffold would provide a platform for mineral deposition in addition to increasing the total 
mineral content. The mineral thus nucleates along the pre-determined scaffold structure resulting 
in trabecular bone-like mineral architecture.  
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Aim 1.2: Effect of silk sponge scaffold stiffness and surface roughness on mineral deposition 
and functional bone formation (Chapter VI) 
Cells have a capability of detecting the mechanical properties, surface topology, and chemistry 
of the substrate they are attached to. Increasing scaffold stiffness alters the environment that cells 
are exposed to while increasing surface roughness does not only alter the contact structure but 
also increases the surface area for cell attachment and protein absorption. This study altered 
scaffold stiffness and surface roughness of silk sponges while maintaining homogeneity of 
scaffold chemical composition through the incorporation of silk micro particles. The effects of 
scaffold stiffness and surface roughness on mineral and protein matrix deposition were 
investigated. 
Aim 1.3: Effects of Bone Sialoprotein on Cell-Mediated Collagen Mineralization (Chapter 
VII) 
Bone sialoprotein (BSP) can specifically bind to collagen and hydroxyapatite via functional 
groups. Previous studies have suggested that BSP can either act as a nucleus for the formation of 
the first apatite crystals on collagen fibril or associate with crystal ghosts to facilitate collagen 
mineralization. However, the dominant BSP mechanism under cell-mediated collagen 
mineralization is unknown. This aim employed tissue engineering approaches to study the effect 
of BSP on osteogenic-induced hMSCs in mineralizing collagen fibril.  
AIM 2: ENGINEERING ARTICULAR CARTILAGES WITH INTEGRATION TO SUBCHONDRAL BONE 
FROM HMSC USING A NOVEL CELL PELLETS COMPRESSION TECHNIQUE 
Introduction to the Problem 
Primary chondrocytes have been largely used in cartilage tissue engineering. Adult chondrocytes 
may be obtained from a patient’s own healthy, non-load bearing cartilage, however, this may 
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lead to donor site morbidity and further tissue degeneration [169]. Chondrocytes from the 
diseased cartilage may also be harvested during preliminary debridement procedures but the 
feasibility of the cell quality and amount of cellular content is uncertain for therapeutic purposes. 
Juvenile chondrocytes, bovine [170] and human [171], have been shown to be superior in term of 
biosynthetic capacity over their adult counterparts. Juvenile bovine chondrocytes encapsulated in 
hydrogel systems recreate and even surpass the properties of native bovine tissue by the temporal 
application of chemical [109] and/or physical factors [172], or a combination of the two [106]. 
However, the clinical utility of juvenile cell sources is limited due to the obvious challenges 
related to tissue procurement. 
Nevertheless, primary cells have limited potential for clinical application. An ability to obtain 
sufficient cell numbers to produce constructs with sufficient mechanical properties is challenging 
due to the reduced biosynthetic activity of cells from patients with advanced stages of the disease 
[173, 174]. Alternatively, undifferentiated cartilage precursor cells, including MSCs isolated 
from patient bone marrow aspirate [175], from adipose tissue [176-179], or from the synovium 
[180-182] have been explored as alternative sources of cells. However, studies have not yet been 
successful in generating functional cartilage from these cell sources.   
Topic Background 
In theory, mesenchymal progenitor cells should have chondrogenic capability since chondrocytes 
originate from mesodermal cells. Cartilage tissue engineering techniques successfully used with 
juvenile chondrocytes were not capable of directing MSCs to form cartilage tissue at the 
functional level. [183]. The cartilage engineered with MSCs was inferior in gene expression, 
matrix production, and mechanical properties to cartilage engineered with juvenile chondrocytes.  
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The inability to form functional cartilage with  hMSCs in hydrogel motivates reconsideration of 
the technique being employed. During tissue development, stem cells undergo chondrogenesis to 
form functional cartilage. Mesenchymal progenitor cells undergo mesenchymal condensation, in 
which the progenitor cells subsequently differentiate into chondroblasts and begin secreting 
cartilage molecules to form the cartilaginous tissue. hMSCs, which are also a type of 
mesenchymal progenitor cell, may require a specific form and function during chondrogenesis.  
 
Cartilage engineered with scaffold-free fabrication techniques, demonstrated better quality than 
MSCs encapsulated in hydrogel. In one study, packing of MSCs was conducted by centrifuging 
cell suspension on transmembrane [184]. The cells proliferated and differentiated, producing 
cartilage matrix with an increase in construct thickness from several microns to hundreds of 
microns. Despite this increase, functional properties of the constructs were not reported in the 
study. This technique was also applied in the engineering of osteochondral constructs with a thin 
cartilaginous layer [185]. Another scaffold-free technique to generate an osteochondral construct 
is to press porous scaffolds into centrifuged cells pellets [134]. Interestingly, both scaffold-free 
methods resulted in cartilage matrix content approaching the value of the native tissue. However, 
due to the properties of the scaffold-free construct, structure and thickness could not be 
controlled. Furthermore, the cartilage tissue formed in the wrong locations was misshaped, or too 
thin.  
Development of Theories and Hypothesis 
Based on the technique of scaffold-free fabrication and cartilage development, this aim improved 
upon methods of engineered cartilage tissue formation from hMSCs; it achieved this by 
governing processes for tissue development in order to control formation of tissue structure. We 
proposed here a novel cell pellet compression technique. In order to mimic the physiological 
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condensation process, hMSCs were centrifuged to form dense, spherical cell pellets. Multiple 
pellets were packed together under compression into a decellularized bone scaffold. This 
technique created a construct with 3 distinguished layers: cell-only layer with precise thickness 
(scaffold-free cartilage region), packed cell penetration into the subchondral bone (interface 
region), and subchondral scaffold (bone region). The packed hMSC pellets were allowed to 
undergo chondrogenesis within a mold to mimic the tight space during physiologic development.  
Experiment: Tissue engineer articular cartilage with cell pellet compression technique 
(Chapter VIII) 
This study optimized the process of engineering articular cartilage from hMSCs via a novel cell 
pellet compression technique. After centrifuging hMSC suspension in chondrogenic media, 
spherical cell pellets formed overnight. The longer the cultivation, the more rigid the pellet 
became, likely as a result of cell packing and extracellular matrix deposition. In order to pack 
multiple pellets together on a subchondral bone, pellets must be rigid enough to hold their shape 
but flexible enough to fuse together and also penetrate the subchondral bone. The study 
investigated the progression of cartilage formation with different level of chondrogenic maturity 
of the hMSC pellets.  
AIM 3: DETERMINING THE REQUIREMENTS TO TISSUE ENGINEER OSTEOCHONDRAL GRAFTS 
Introduction to the Problem 
Successfully engineered osteochondral grafts should be populated with autologous or non-
immunogenic cells to prevent immune rejection and facilitate adaptation. In addition, the 
fabrication technique must result in a controlled graft size and shape to match that of the defect. 
Since an osteochondral graft is a complex tissue consisting of bone, cartilage, and the integrated 
interface, engineering clinically relevant construct in vitro is a challenging task. The cells must 
be seeded to fully occupy volume for tissue formation. Adequate factors must be supplied to 
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maintain cellularity and spatially differentiate stem cells into tissue-specific lineages in a defined 
region (i.e. chondrogenesis in the articular region, bone formation in the subchondral bone 
region, and an integrating interface in between the two tissues). In vitro cultivation of 
osteochondral grafts with clinically relevant sizes and anatomical shapes requires an innovative 
bioreactor. Although a perfusion bioreactor has been successfully employed to engineer bone 
constructs, there is no successful bioreactor designed for complete osteochondral tissue 
engineering. This aim investigated the regulation of spatially controlled hMSC development to 
form osteochondral tissues in vitro. 
Topic Background 
Previous attempts to spatially control cartilage and bone formation employed pre-differentiating 
stem cells into specific lineages prior to scaffold seeding. Tuli et al. [134] press-coated MSCs on 
PLA constructs and cultured them in chondrogenic media for 2 or 5 weeks prior to seeding 
osteogenic-induced MSCs from the same source. The constructs were then cultured in cocktail 
media (mixture of chondrogenic and osteogenic supplements) up to 10 weeks. The results 
showed distinguished chondrogenic and osteogenic development in desired regions with the 
presence of a cartilage-bone interface.  
Augst et al. separately induced hMSC-seeded silk sponges in chondrogenic or osteogenic media 
for 3 weeks. The two constructs were attached together and cultured in chondrogenic or 
osteogenic media for an additional 3 weeks to create osteochondral grafts with integration [136]. 
The constructs were cultured in rotating-wall vessel bioreactors to enhance transport.  Pre-
differentiation regulates MSCs to develop into specific lineages and results in spatially 
controlled, tissue-specific behavior (i.e. cartilage and bone formation). The study demonstrated 
that TGF-β played an important role in integrating bone and cartilage surfaces. The pre-
differentiation technique demonstrated a well-developed strategy to spatially control tissue 
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formation. However; the shape and size of the constructs and tissue mechanics were not 
comparable to native tissue [134, 185]. 
Development of Theory and Hypothesis 
The ultimate goal for a tissue engineer is to develop a system that allows fabrication of grafts 
with physiologic properties. Ideally, osteochondral grafts should have anatomical shape, contain 
a stiff subchondral bone region with osteogenic and osteointegrative properties, a physiologically 
thick and functional cartilage layer, and strong integration of the two tissues. hMSCs have the 
capability to form bone and cartilage in vitro through induction of media soluble factors, 
mechanical cues, and bioactive scaffolding materials but are nonetheless difficult to control 
during this complex tissue formation. Successful engineering of osteochondral grafts from hMSC 
requires spatial control of hMSC differentiation and stimulation of the native tissue matrix 
formation and assembly. This aim was to determine the essential criteria for developing a 
bioreactor system for engineering osteochondral grafts. 
Experiment: Spatial regulation of human mesenchymal stem cell differentiation in engineered 
osteochondral constructs: effects of pre-differentiation, soluble factors and medium perfusion 
(Chapter IX) 
This study investigated the effect of pre-differentiation, soluble factors, and medium perfusion in 
spatially regulated osteochondral tissue formed from hMSCs. Bi-phasic constructs can be formed 
by pre-differentiation of hMSC or by distinctly supplying lineage-specific factors. Perfusion 
bioreactors have been previously shown to separately enhance cellularity and extracellular 
matrix formation in engineered bone and cartilage tissues. The combined effects of  hMSC pre-
differentiation and the perfusion bioreactor in engineering osteochondral constructs have not yet 
been investigated. Determining the effect of hMSC pre-differentiation, soluble factors, and 
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medium perfusion on osteochondral tissue development provided new insights into the essential 




Aim 1.1: Nucleation and growth of mineralized bone matrix on silk-
hydroxyapatite composite scaffolds 
ABSTRACT 
We describe a composite hydroxyapatite (HA) – silk fibroin scaffold designed to induce and 
support the formation of mineralized bone matrix by human mesenchymal stem cells (hMSCs) in 
the absence of osteogenic growth factors. Porous three-dimensional silk scaffolds were 
extensively used in our previous work for bone tissue engineering and showed excellent 
biodegradability and biocompatibility. However, silk is not an osteogenic material and has a 
compressive stiffness significantly lower than that of native bone. In the present study, we 
explored the incorporation of silk sponge matrices with HA (bone mineral) microparticles to 
generate highly osteogenic composite scaffolds capable of inducing the in vitro formation of 
tissue-engineered bone. Different amounts of HA were embedded in silk sponges at volume 
fractions of 0%, 1.6%, 3.1% and 4.6% to enhance the osteoconductive activity and mechanical 
properties of the scaffolds. 
The cultivation of hMSCs in the silk/HA composite scaffolds under perfusion conditions resulted 
in the formation of bone-like structures and an increase in the equilibrium Young’s modulus (up 
to 4-fold or 8-fold over 5 or 10 weeks of cultivation, respectively) in a manner that correlated 
with the initial HA content. The enhancement in mechanical properties was associated with the 
development of the structural connectivity of engineered bone matrix. Collectively, the data 
suggest two mechanisms by which the incorporated HA enhanced the formation of tissue 
engineered bone: (i) the increased osteoconductivity of the material led to increased bone matrix 




Bone repair procedures often require a replacement graft to restore the function of damaged or 
diseased tissue. These grafts are in most cases derived from tissues harvested from a second 
anatomic location of the same patient (autografts) or from other patients (allografts).  Autografts 
have been considered the gold standard for bone repair.  However, limited supplies of suitable 
bone grafts, donor site morbidity and difficulties in shaping explanted bone have posed 
significant problems. On the other hand, allografts have a risk of disease transmission [186].  
These limitations provide incentives for finding alternative methods. Tissue engineered bone 
offers a promising alternative treatment for clinical use, as well as a controllable model system 
for studies of cell function, developmental biology and pathogenesis [187, 188].  
Successfully engineered bone grafts must be biocompatible and meet certain minimal 
mechanical requirements to be functional. The scaffold material provides many of the 
mechanical properties of the engineered graft.  Organic- and polymer-based scaffolds are easily 
fabricated into different structures but often do not have the desired compressive modulus [137, 
189-191]. Alternatively, ceramic scaffolds are stiffer but are often fragile and have low porosity, 
resulting in loosening or fracture of implants in clinical applications [192].  Combining both 
types of materials to form composite scaffolds can enhance the mechanical and biochemical 
properties of scaffolds used for bone tissue engineering. 
In this study, silk protein and hydroxyapatite (HA) ceramic were chosen because of their 
biocompatibility and osteoconductivity, and ease and reproducibility of fabrication.  Silk sponges 
have been used extensively in bone tissue engineering approaches with human mesenchymal 
stem cells (hMSCs) and were shown to facilitate bone formation in vitro and in vivo [88, 136, 
137, 193]. Silk prepared with organic solvent (hexafluoroisopropanol: HFIP) and salt leeching 
allows the fabrication of biocompatible scaffolds with high silk content, high porosity, and good 
inter-pore connectivity [137, 193, 194]. HA is biocompatible, bioactive, osteo-inductive and can 
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slowly be replaced by host bone after implantation [195-198]. We hypothesized that embedding 
HA micro-particles within the walls of silk sponges would improve scaffold stiffness and 
enhance hMSC differentiation resulting in the development of tissue engineered bone grafts with 
higher mineral content and improved compressive stiffness. We therefore examined the effects 
of scaffold properties on the structural and mechanical outcomes of engineered bone grafts by 
incorporating various amounts of HA mineral in porous silk scaffolds.  
Bone-like constructs have been prepared in vitro by culturing hMSCs seeded into biomaterial 
scaffolds. HMSCs offer several advantages: they can be obtained autologously, expanded in vitro 
to provide sufficient cell numbers, differentiated into osteoblasts [199-202] and have shown 
promising results in clinical models [203]. In this study, silk-HA scaffolds were seeded with 
hMSCs and cultured in perfusion bioreactors, which improve cell distribution and bone 
formation inside the scaffolds [78, 89, 204]. Perfusion provides adequate nutrient and oxygen 
supply as well as cell stimulation through fluid shear stress, which enhances hMSCs osteogenic 
differentiation [89, 205-207].  Constructs were cultured for up to 10 weeks before being 
harvested and analyzed for bone tissue formation.   
MATERIALS AND METHODS 
Scaffold Fabrication 
All reagents were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise specified.  
Silk fibroin was extracted from Bombyx mori cocoons utilizing our previously developed 
methods [12].  Briefly, the sericin was removed by boiling the cocoons in a 0.02 M Na2CO3 
solution for 30 minutes.  The resulting fibers were then dissolved in 9.3 M LiBr for 4 hours at 
60ºC and then subsequently dialyzed against ultrapure water for 48 hours to remove residual 
LiBr.  The aqueous silk solutions were lyophilized and redissolved in HFIP to yield a solution of 
16 w/v%.  The method for fabricating HA-incorporated silk sponges is shown in Fig.V-1A. 
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Reinforcement of the scaffolds was achieved by mixing HA into the NaCl particles and pouring 
the silk solution over the mixture.  Scaffolds were prepared with pore sizes ranging between 500 
and 600 mm using granular NaCl as a porogen.  Once the scaffolds solidified, they were treated 
with methanol for 1-2 days to induce β-sheet formation and then the salt was subsequently 
extracted by immersion in fresh water for 48 hrs. Scaffolds were cut and cored into cylinders of 4 
mm in diameter by 4 mm thick and were sterilized in 70% ethanol overnight and incubated in 
culture medium over night before seeding.  
Four groups of scaffolds with different content of HA-silk composition were fabricated with 
mixtures of Silk:HA:Salt ratios by weight of 1:0:20, 1:0.5:20, 1:1:20, and 1:1.5:20. The volume 
fractions of silk and HA in the porous scaffold were calculated using the amount of the materials 
added and their densities which are 1.4 g/ml and 3.16 g/ml, respectively. As a result, the 
designated group names were based on approximated HA volume fraction in the scaffolds that 
were 0%, 1.6%, 3.1%, and 4.6% HA, respectively. 
Scanning Electron Microscopy 
SEM was performed to determine pore structure and surface topography on two scaffolds of each 
group. In brief, scaffolds were washed in PBS and then fixed in 2% glutaraldehyde in PBS 
overnight. Constructs were washed in graded ethanol solution up to 70% and then freeze-dried 
overnight in a lyophilizer. Dried samples were coated with gold and imaged at 200x and 1000x 




Figure V-1: Experimental design (A) Silk-HA composite scaffold fabrication process. (B) 
Experimental design to study the effects of embedded HA content in silk sponge in formation of 
tissue engineered bone constructs. Four types of scaffolds (0% HA, 1.6% HA, 3.1% HA, and 
4.6% HA) were seeded with hMSCs and cultured in osteogenic media under perfusion bioreactor 
for 5 and 10 weeks. Unseeded 0% HA and 4.6% HA were also cultured for 5 weeks. 
Human Mesenchymal Stem Cell Cultivation and Seeding 
Fresh bone marrow aspirates were obtained from Cambrex Life Sciences (East Rutherford, NJ), 
isolated and characterized as previously described [78]. Cells were expanded in high-glucose 
DMEM supplemented with 10% FBS, 1% pen-strep, and 0.1 ng/mL bFGF. The hMSCs were 
cultured up to the third passage and then used for seeding the scaffolds. The seeding process was 
previously described [87, 137]. In brief, scaffolds were seeded at the concentration of 30×106 
cells/ml scaffold volume. A 40-μl aliquot of cell suspension was pipetted onto blot-dried 
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scaffolds and allowed to percolate through. The scaffolds were flipped 180° every 20 minutes 
and 10 μl of media was added to prevent the cells from drying out. Constructs were cultured with 
osteogenic medium (low-glucose DMEM supplemented with 10% FBS, 10 nM dexamethasone, 
10 mM sodium-β-glycerophosphate, and 0.05 mM ascorbic acid-2-phosphate) for 3 days before 
harvested for Day 0 sample and insertion into the bioreactor.  
Bioreactor Cultivation 
A perfusion bioreactor developed in our laboratory, described and used previously [87, 204], was 
employed in this study. In brief, 6 scaffolds were placed in each bioreactor and medium flow rate 
was set to provide the superficial velocity of medium through the scaffolds at 400 μm/s. One half 
of the medium volume was replaced twice a week and scaffolds were harvested for analysis at 
weeks 5 and 10 (Fig.V-1B). The studies were conducted twice 6 month apart with different 
batches of scaffolds to ensure reproducible results. Since the results of the two studies were 
similar, they were pooled together. Two additional experimental groups (unseeded 0% HA and 
4.6% HA) were performed in the repeat experiment (Fig.V-1B). 
Cell Viability 
After harvest at day 0 and week 10, two half scaffolds per group were washed in PBS and 
stained with 1 mM calcein and 4 mM ethidium in PBS for 30 min. The images were taken with a 
confocal microscope (Leica, Germany; 20 slices at 10 μm thick).  
Biochemical Assay 
Constructs were cut in half in the longitudinal direction, washed in PBS and the wet weights 
were determined. For DNA analysis, the samples (n=8) were stored at -20°C in 1 ml of digestion 
buffer (10 mM Tris, 1mM EDTA and 0.1% Triton X-100) with 0.1 mg/ml of proteinase K in 
micro-centrifuge tubes. Samples were then thawed and maintained in this solution overnight at 
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56°C to extract the DNA. The DNA content was determined using a Picogreen assay (Molecular 
Probes, OR). For calcium content analysis, the samples (n=4) were quickly frozen in liquid 
nitrogen and stored at -20°C. Calcium was extracted in 500 μl of 5% TCA solution using a bead 
beater and analyzed with a Calcium (CPC) Liquicolor® kit (Stanbio Laboratory, USA).  
Mechanical Testing 
The equilibrium compressive Young’s modulus (n=8 per group) was determined at day 0, week 
5, and week 10 in unconfined compression at wet conditions using a modification of an 
established protocol [103]. An initial tare load of 0.2 N was applied and was followed by a 
stress-relaxation step where specimens were compressed at a ramp velocity of 1% per second up 
to 10% strain and maintained at the position for 1800 s. The Young’s modulus was obtained 
from the equilibrium forces measured at 10% strain. Mechanical properties of decellularized 
trabecular bovine bones were also measured with the same method. 
Micro Computerized Tomography 
μCT imaging was performed using a modification of a previously used protocol [208] with the 
following settings: voltage 55kV, current 0.109 mA, slice thickness 21 μm, and inter-slice 
spacing 22 μm. Scaffolds were scanned prior to seeding and after cultivation. Immediately after 
harvesting, full constructs (n=6 per group) were aligned and stabilized along their axial direction 
in PBS inside microcentrifuge tubes. The tubes were placed in the specimen holder of a vivaCT 
40 system (SCANCO Medical AG, Basserdorf, Switzerland). Constructs were scanned at 21 μm 
isotropic resolution. The bone volume was obtained using a global thresholding technique with 
threshold at 220. The structural parameters, which are bone volume (BV), bone volume fraction 
(BVF), connectivity density (Conn.D), trabecular number (Tb.N), trabecular thickness (Tb.Th), 
and trabecular spacing (Tb.Sp) were determined with the structural reconstruction. 
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Figure V-2. Calculated volume fraction of silk and HA mineral and SEM images of 0% HA, 
1.6% HA, 3.1% HA, and 4.6% HA scaffolds. 200x SEM image showed porous scaffold with 
interpore connectivity (bar: 200 μm). 1000x SEM image illustrated the different in surface 
topography of the scaffolds (bar: 20 μm). 
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Histology and Immunohistochemistry 
Constructs were washed in PBS, fixed in 10% formalin, embedded in paraffin, sectioned into 4 
μm slices and stained with haematoxylin and eosin (H&E), and Von Kossa. 
Immunohistochemistry staining for collagen type I, bone sialoprotein (BSP), and osteopontin 
was also conducted as previously described [87].  
Statistical Analysis 
Multiway Analysis of Variance (ANOVA) to analyze groups at the same time point and within 
group at different time points was carried out followed by Tukey’s post hoc analysis using 
STATISTICA software, with p<0.05 being considered as significant. 
RESULTS 
Scaffold Fabrication 
The inter-pore connectivity of the scaffolds was maintained with the incorporation of HA into 
the silk sponges, while minimally reducing the porosity as seen in low magnification SEM 
images (Fig.V-2). The pore size of the scaffolds in all groups ranged between 400-600 μm, 
which is equivalent to the size of the salt particles that were used in the process. High 
magnification SEM images showed an increase in scaffold surface roughness qualitatively as 
more HA was added, but with less distinct differences between 3.1% and 4.6% groups (Fig.V-2). 
The incorporated HA was trapped within the silk structure and an increase in wall thickness was 
observed.  By converting material mass introduced into the scaffold into volume, the total 
material volume fraction within the 0%, 1.6%, 3.1%, and 4.6% HA groups were 7.18, 8.66, 
10.04, and 11.40%, respectively; thus, a decrease in void volume was observed as more HA was 
incorporated. In addition, incorporation of HA gradually increased scaffold equilibrium 
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compressive Young’s modulus measured in the hydrated state, from 120.8±48.7 kPa in 0% HA 
group to 251.1±116.9 kPa in 4.6% HA group (Fig.V-5A).  
 
 
Figure V-3. (A) DNA content before and after cultivation in perfusion bioreactor for 5 and 10 
weeks (Line represents a statistically significant difference between time point of the same 
scaffold group; a, b represent statistically significant differences from 0% HA and 1.6% HA, 
respectively, at the same time point). (B) Live/Dead image of cells inside the scaffolds before 
and after cultivation for 10 weeks (scale bar: 200 μm). 
Cell Viability and DNA Content 
After 5 and 10 weeks of culture, the DNA content significantly increased from Day 0 in all 
groups and as much as 4 fold in the 4.6% HA (Fig.V-3A). Although the average DNA content of 
the 0% HA was significantly higher than in the 3.1% and 4.6% HA groups at Day 0, the DNA 
content was not significantly different after 5 and 10 weeks of culture. Live/Dead assay showed 
good cell viability after seeding and after 10 weeks of culture with an increase in cell content 
over the culture period (Fig.V-3B). 
Mineral Content and Micro-Structure 
The structure of the tissue engineered bone developed over 5 and 10 weeks of culture (Fig.V-4).  
In the 0% HA group, the tissue engineered bone had no detectable mineral with μCT and, while 
over 10 weeks, the mineral deposited developed into spherical-like structures (Fig.V-4). 
Constructs from the 1.6% HA group developed into trabecular-like structures over the culture 
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period with some aggregates of spherical-like structures (Fig.V-4). In contrast, constructs in the 
3.1% and 4.6% HA groups developed trabecular-like architectures with high structural 
connectivity (Fig.V-4).  
 
 
Figure V-4. Reconstructed 3D μCT images of the tissue engineered bone construct before and 
after cultivation for 5 and 10 weeks of all groups (scale bar: 2 μm). 
Quantification of morphological parameters confirmed development of trabecular-like structures 
in 3.1% and 4.6% HA groups (Fig.V-5). BV, BVF, Conn.D, Tb.N, Tb.Th, and Tb.Sp approached 
the values of native bovine trabecular bone (dash lines) determined in our laboratory with the 
same scanning method. BV, BVF, and Conn.D significantly increased and more than doubled 
over 10 weeks of culture in the groups with mineral. The BVF  (Fig.V-5D) of 3.1% and 4.6% 
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HA on average were 0.029±0.028 and 0.068±0.038 at day 0 and reached 0.097±0.021 and 
0.126±0.019 at 5 weeks and 0.142±0.062 and 0.156±0.033 at 10 weeks, respectively. The 
Conn.D (Fig.V-5E) of 3.1% and 4.6% HA increased significantly from 0.78±1.72 and 2.34±2.57 
1/mm3 to 4.18±1.85 and 8.76±2.40 1/mm3 at week 5 and to 9.24±8.53 and 12.83±5.43 1/mm3 at 
week 10, respectively.  Tb.N and Tb.Th increased over time while the Tb.Sp decreased (Fig.V-
5F-H) in all groups except 0% HA in which Tb.Sp at day 0 could not be determined. When 
unseeded 0% HA and 4.6% HA were cultured for 5 weeks, all parameters remained the same as 
the day 0 value, indicating that changes in mineralization were cell-based (data not shown).  
Mechanical Properties 
The equilibrium Young’s modulus gradually increased over time in all groups (Fig.V-5A). The 
moduli of scaffolds containing 0%, 1.6%, 3.1%, and 4.6% HA were 121±49, 140±70, 201±90, 
and 251±117 kPa, respectively, at Day 0. By 5 weeks, the moduli of scaffolds containing 0%, 
1.6%, 3.1%, and 4.6% HA reached, 340±99, 594±234, 865±347, and 1005±381 kPa, 
respectively. The modulus of the 3.1% and 4.6% HA were significantly higher than the modulus 
of the 0% HA. Equilibrium Young’s moduli of unseeded 0% and 4.6% HA were not 
significantly different from day 0. By 10 weeks, the moduli of scaffolds containing 0%, 1.6%, 
3.1%, and 4.6% HA reached on average 0.532±0.180, 0.869±297, 1.600±0.577, and 1.670±0.528 
MPa, respectively. The moduli of scaffolds containing 3.1% and 4.6% HA were significantly 
higher than the moduli of both 0% and 1.6% HA. The equilibrium Young’s moduli of 
decellularized bovine trabecular bone determined in our laboratory with the same method ranged 
between 5-40 MPa. The equilibrium Young’s moduli of unseeded 0% HA and 4.6% HA 
remained unchanged from the Day 0 value. 
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Figure V-5. Development of tissue engineered bone constructs over 5 and 10 weeks of 
cultivation: (A) Equilibrium Young’s Modulus, (B) calcium content, and bone structural 
parameters determined by μCT analysis; (C) BV, (D) BVF, (E) Conn.D, (F) Tb.N, (G) Tb.Th, 
and (H) Tb.Sp (Dash line indicates average value of decellularized native trabecular bovine 
bone. Solid tree line represents a statistically significant difference between time point of the 
same scaffold group; a, b, c represent statistically significant differences from 0% HA, 1.6% HA, 
and 3.1% HA, respectively, at the same time point). 
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Calcium Content 
The calcium content of scaffolds increased over time but the increases were not statistically 
significant within each group (Fig.V-5B). At Day 0, the calcium content of scaffolds containing 
0%, 1.6%, 3.1%, and 4.6% HA were 0±0, 1.18±0.85, 2.21±1.32, and 3.47±1.00 mg per scaffold, 
respectively. Over 10 weeks, the average calcium content increased by 0.24, 0.40, 0.97, and 0.90 
mg per scaffold for scaffolds containing 0%, 1.6%, 3.1%, and 4.6% HA, respectively. Both 
unseeded 0% and 4.6% HA did not show an increase in average calcium content (data not 
shown). 
 
Figure V-6. Histology and immunohistochemistry of the constructs before and after cultivation: 
(A) H&E, (B) Von Kossa, (C) Collagen Type I, and (D) Bone sialoprotein (bar: 200 μm). 
Histology and Immunohistochemistry 
H&E (Fig.V-6A) shows increased cell content in pore spaces within the first 5 weeks of culture 
in accordance with DNA quantification. As seen by von Kossa staining, there was an increase in 
calcium content within scaffold structure as more HA was incorporated and this resulted in 
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thicker walls, similar to the structures seen by SEM. Over 5 and 10 weeks, the 0% and 1.6% HA 
exhibited a deposition of mineral in the scaffold pores while such evidence was not observed in 
the 3.1% and 4.6% HA. The mineral inside the pore space of 0% HA aggregated forming 
granular structures. Collagen type I (Fig.V-6C), BSP (Fig.V-6D), and OCN (data not shown) 
immunohistochemistry staining indicated an increase in bone matrix deposition over time in all 
group. The staining of the proteins was most intense in 3.1% and 4.6% HA at 10 weeks of 
culture. 
DISCUSSION 
Silk has shown significant promise as a biomaterial for bone tissue engineering scaffolds [189, 
209, 210]. However, silk by itself is not osteogenic, and the mechanical properties of silk 
scaffolds are considerably lower than those of native bone (Young’s moduli ~ 100 kPa vs. ~ 10 
MPa for bone). In the present study, we investigated the potential of HA micro-particles to 
improve the osteogenic and mechanical properties of silk scaffolds, and enhance the in vitro 
formation of bone-like tissues by hMSCs without the use of osteogenic growth factors such as 
BMPs.  
We successfully fabricated biocompatible HA-embedded silk scaffolds while maintaining pore 
size and interconnectivity (Fig.V-2).  The incorporation of HA altered scaffold surface 
chemistry, increased surface roughness (Fig.V-2) and increased the stiffness of unseeded 
scaffolds (Fig.V-5A) We confirmed that HA was osteoinductive as the mineral deposition 
increased in a dose-dependent response to the initial amount of HA as demonstrated with μCT 
imaging (Fig.V-4).  The major contribution of the HA was to guide the deposition of the newly 
formed bone mineral to provide significantly higher construct mechanical stiffness at the end of 
cultivation. Previous findings suggest that the microarchitecture (topography, orientation and 
connection of trabeculae), in addition to bone volume fraction, are important in governing the 
mechanical properties of trabecular bone [208, 211].  
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The compressive (Young) modulus of engineered bone constructs increased as much as 8-fold 
for HA scaffolds when compared to silk alone (Fig.V-5A), approaching that of the decellularized 
bovine trabecular bone measured via the same testing method.  We found that 3.1% HA mineral 
provided sufficient bioactivity to direct hMSCs to form a trabecular-like mineral structure. Thus, 
the significant increase in the strength of engineered bone constructs in the present study was 
likely due to the combination effect of the changes in the amount of mineral (as seen from 
increased bone volume fractions, Fig.V-5D) and the improved structure (as seen from increased 
bone interconnectivity, Fig.V-5E). In contrast, an increase in the trabecular thickness of pure silk 
scaffolds with no concomitant change in connectivity confirmed an increase in size of spherical 
mineral deposits, which did not significantly improve the mechanical properties [88, 90, 136, 
137]. In all cases, histological von Kossa staining confirmed the μCT data.  
Calcium production by the differentiated hMSCs correlated with the amount of embedded HA in 
a dose dependent manner up to 3.1% HA and remained constant thereafter, which was consistent 
with prior reports [212-214]. With the same number of cells among the study groups, the amount 
of calcium deposition in the 3.1% and 4.6% HA groups was in creased by almost 4-fold as 
compared to the 0% HA group. However, due to the high initial values of calcium in the HA 
scaffolds compared to the amount of calcium produced by the cells, the increase in calcium 
content was steady but not statistically significant over time.  Previous studies reported calcium 
production by hMSCs ranging from 0.25 to 8 μg/ng DNA after 5 weeks of culture in osteogenic 
medium supplemented with BMP-2 [90, 137, 215]. Calcium production in the present study was 
0.11 μg/ng DNA over 10 weeks, a lower amount as no BMP-2 was supplemented to the cultures.  
An interesting observation was that the increase in bone volume (Fig.V-5C) analyzed by μCT 
was substantially higher than the increase in calcium content (Fig.V-5B). It appears that since 
μCT employed in this study has a resolution of 21 μm and the largest HA particles observed by 
SEM imaging was approximately 20 μm, not mineral was detected by μCT. Therefore, the 
change in bone volume measured by µCT included both the initially undetected HA 
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microparticles that grew larger and the new mineral produced by cells. These HA microparticles 
therefore played a role of nucleation sites that facilitated the formation of a highly connected 
mineral structure. In addition to the production of mineral, the production of bone matrix 
proteins was also dependent on HA concentration, as seen with collagen type I and BSP (Fig.V-
6C&D), and consistent with the effect of HA mineral on gene expression previously reported 
[58, 216]. The unseeded scaffolds of the 0% and 4.6% HA groups did not demonstrate changes 
in mineral structure, calcium content, bone matrix production or mechanical strength, indicating 
that these changes were cell-mediated.  
It is also possible that the enhanced outcomes in the HA scaffolds may be explained in part due 
to the changes in the initial stiffness and surface roughness, both of which may influence cellular 
responses.  However, initial scaffold stiffness was not significantly altered among the groups and 
other forms of modifying silk scaffolds have provided considerably higher initial compressive 
moduli but did not elicit such significant cell-mediated improvements [193]. Therefore, it is 
unlikely that the surface roughness of the scaffolds was the main reason for large improvement 
in mechanical properties, as a previous attempt to mineralize silk scaffolds through surface 
coating with HA did not elicit the same response [216]. By incorporating HA into the walls of 
the silk scaffolds, we provided the hMSCs with a more osteoinductive surface, but more 
crucially, the data suggests that the HA microparticles served as nucleation sites that directed 
mineral deposition, leading to an enhanced trabecular structure, increased connectivity and 
superior mechanical properties of the resulting tissue grafts.  This is shown schematically in 
Figure V-7.  Such a mechanism suggests that the spatial proximity of HA microparticles to each 
other is an important parameter and may also explain why the increase from 3.1% to 4.6% HA 
did not elicit a pronounced difference in the final outcome, as a certain threshold distance 
between neighboring particles had been attained. 
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Figure V-7. Schematic of mineralization process. Yellow, blue and red regions represent silk, 
premineralized HA, and new mineral, respectively. Arrows indicate the connection of the new 
mineral structure. In 0% HA, newly produced mineral localized within the pore space and grew 
larger in size over time resulting in spherical-like mineral structure. In 1.6% HA, new mineral 
nucleated from premineralized HA as well as was deposited into the pore space. In 3.1e4.6% 
HA, the newly produced mineral nucleated from the premineralized HA. As the structure grew, 
structural connections occurred. 
CONCLUSIONS 
The effect of incorporating the HA mineral into porous silk scaffolds was investigated for tissue 
engineered bone formation with hMSCs. The HA mineral enhanced hMSCs osteogenic 
differentiation and provided a platform for bone-like structure formation when adequate HA 
content was incorporated. The HA mineral provided a platform for the formation of engineered 
bone by hMSCs, both through the osteoconductivity of the material and by providing nucleation 




Aim 1.2: Effect of silk sponge scaffold stiffness and surface roughness on 
mineral deposition and functional bone formation 
INTRODUCTION 
Large bony defects from either non-unions or trauma, can pose a significant problem for a 
patient and often require surgical intervention [217]. Current treatments rely on autografts or 
allografts, each of which has associated risks. Autografts require an additional surgical site, with 
a restricted amount of available donor tissue, and are often associated with donor site morbidity. 
In contrast, the issue of limited donor material is alleviated with the use of allografts, although 
there is a potential risk of disease transmission and possible long-term complications [186, 218]. 
In some cases, it has been shown that progenitor cells can be injected into the defect to aid in 
tissue repair. Although this approach has shown some promise, difficulty remains with 
immobilizing the cells at the site of bone regeneration. Therefore, tissue engineered constructs 
have been considered in order to sustain cells at the implant site and to act as conduits for growth 
factor, antibiotic, or therapeutic drug release [186].  
There are several biological requirements that must be met for a successful tissue engineered 
graft device. Specifically for bone tissue, the device should be (i) biocompatible, (ii) 
osteoconductive, (iii) osteoinductive to attract progenitor cells in order to aid in regeneration, (iv) 
osteogenic to ensure osteoid deposition, and ultimately (v) osteointegrative. Additionally, 
material characteristics of scaffolding that msut be considered include surface roughness, 
mechanical integrity, and porosity [186]. Many polymeric materials, both natural and synthetic, 
have been studied for use as bone scaffolding substrates, including collagen, hyaluronic acid, 
chitosan, poly(L-lactide-co-glycolide) (PLGA), polymethylmethacrylate (PMMA), 
polycaprolactone (PCL), as well as several ceramic materials such as calcium phosphate, calcium 
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sulfate, and bioactive glass [219-222]. However, the search for a perfect bone scaffold that 
fulfills all biological criteria still continues. In addition to biological factors, an ideal bone tissue 
scaffold should also satisfy several physical requirements. For instance, a mismatch between the 
biomechanics of the orthopedic biomaterial and the native tissue can also be a source of failure 
[223]. Often in literature, the biomaterial scaffolding is too compliant to simulate native bone. 
For example, direct implementation of collagen for bone tissue engineering has been limited due 
to the relatively weak mechanical characteristics with respect to the native bone [224, 225]. 
Scaffolds made of collagen-based demineralized bone matrix (DBM) reportedly had a wet 
compressive modulus of 4.1 kPa [226]. This value increased to 31 kPa by cross-linking the DBM 
with heparin. Despite the significant improvement in rigidity, these values are still too low in 
comparison with native bone tissue [227]. 
To improve the mechanical properties and osteoinductive potential of bone scaffold materials, 
the use of composites has been explored. In many cases, a polymer matrix is augmented by the 
inclusion of a ceramic material such as hydroxyapatite (HAP), tricalcium phosphate, or bioactive 
glass [228-231]. For example, by synthesis of PLGA microspheres in the presence of amorphous 
calcium phosphate followed by sintering produces a porous scaffold with interconnected 
structures that contains mechanical properties within the range of the trabecular bone in the dry 
state [229]. However, the dependence of the mechanical properties of these materials in the 
hydrated state has not been reported. In another study, dispersing nano-hydroxyapatite (nHAP) 
throughout silicone rubber provided a more favorable matrix for cell attachment, viability, and 
proliferation of murine preosteoblasts as compared to the pure silicone rubber [231]. In these 
cases, a polymer matrix was mixed with a ceramic filler. This is in contrast to the present study 
where we reinforce a silk fibroin matrix with a silk fibroin microparticle filler to create a 
protein–protein composite. By controlling the interfacial bond between the two phases, we can 
improve the mechanical performance through interfacial stability. 
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Bombyx mori (silkworm) silk fibroin’s desirable properties make it a potent alternative to many 
other biodegradable biopolymers for bone tissue engineering. Silk fibroin possesses a β-sheet 
(crystalline)-rich structure that provides superior physical characteristics, such as stiffness and 
toughness to most natural and synthetic polymers. For example, individual fibroin filaments have 
an ultimate tensile strength (UTS) between 610 and 690 MPa and a modulus between 15 and 17 
GPa. In contrast, the UTS for rat tail type I collagen and polylactic acid (PLA) range between 0.9 
and 7.4 MPa and 28 and 50 MPa, respectively. The moduli for these materials are 1.8-46 MPa, 
for collagen, and 1.2–3.0 GPa for PLA [232]. In addition to the mechanical properties, silk 
fibroin has favorable biological characteristics, such as excellent biocompatibility with low 
inflammatory and immunogenic response. As a consequence, silk has been used as a suture 
material for centuries and is an FDA approved biomaterial. Moreover, due to its amphiphilic 
nature, silk fibroin can easily be processed into fibers, hydrogels, thin films, sponges, and 
composite materials, with degradation rates that can be tuned from days to years. Additionally, 
silk can be produced in large quantities and at reasonable costs due to the commodity textile 
business. Due to the above properties and the ability to be processed into a range of material 
formats, silk is an excellent candidate material for bone tissue applications. 
The goal of the present work was to investigate the effect of silk sponge stiffness and surface 
roughness on in vitro engineered bone development. Previously, no increase in either material 
strength or stiffness was observed after depositing hydroxyapatite (HAP) on the surface of 
preformed silk scaffolds, despite enhanced bone-specific development [216]. A recent study has 
shown that silk sponges can be reinforced by loading the matrix phase with different 
concentrations of silk microparticles in order to address these strength limitations [233]. Here, 
we intend to exploit the impressive mechanical properties of these silk–silk composite materials. 
By adding silk microparticles to the matrix of a silk sponge, both the surface roughness and 
mechanical properties can be enhanced. We systematically investigated the effect oftwo 
modifications of silk scaffolds on human stem cell differentiation and the development of 
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engineered bone. The modifications were as follows: (i) an increase in scaffold stiffness by 
alteration of total silk fibroin concentration (resulting in a smooth, single phase porous scaffold) 
and (ii) reinforcement by embedding silk microparticles (resulting in two-phase porous scaffolds 
with strong interfacial compatibility and surface roughness). Direct effect of scaffold surface 
roughness was investigated by adjusting the two silk modifications to exhibit similar stiffness. 
Table VI: Composition and mechanical properties of the four types of scaffolds: material 
compositions and equilibrium compressive moduli. (^significant difference within SS and PS 
group; *significant difference from their respective SS groups) 
Scaffolds Concentration of silk fibroin (g/ml) 
Concentration of silk 
micro particles (g/ml) 
Equilibrium compressive 
modulus (kPa) 
16-0 (SS) 0.16 0 61±37 
32-0 (SS) 0.32 0 519±158^ 
16-16 (PS) 0.16 0.16 402±101* 
32-16 (PS) 0.32 0.16 900±211^* 
MATERIALS AND METHODS 
Fabrication of porous silk scaffolds with embedded silk microparticles 
Hexafluoro isopropanol (HFIP)-silk solution was fabricated from cocoons of Bombyx mori as 
previously described [234]. One ml of silk solution (16 or 32 w/v%) was added into the glass 
container containing 3.4 g granular NaCl (particle size; 500-600 µm) with or without silk 
particles (3.1 ± 1.84 µm, 16 w/v%), centrifuged, and dried at room temperature. After 2 days of 
MeOH treatment, the NaCl porogens were extracted to produce cylindrical microparticle-
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embedded silk sponges (12 mm in diameter). Two types of silk sponges (SS group: 16-0 and 32-
0) and two types of micro-particles-embedded silk sponges (PS group: 16-16 and 32-16) were 
fabricated (Table VI). Scaffolds were cut and cored into cylinders 4 mm diameter x 4 mm thick. 
Scanning electron microscopy 
SEM was performed to determine pore structure and surface topography on two scaffolds of 32-0 
and 16-16 samples. In brief, scaffolds were washed in PBS and then fixed in 2% glutaraldehyde 
in PBS overnight. Constructs were washed in buffer and freeze-dried overnight in a lyophilizer. 
Before imaging, samples were coated with gold and palladium and used for SEM.  
Compressive mechanical testing 
The equilibrium compressive Young’s modulus (n=4 per group) was determined at day 0, and at 
week 5 under unconfined compression in wet conditions using a modification of an established 
protocol [103]. An initial tare load of 0.2 N was applied and was followed by a stress-relaxation 
step where specimens were compressed at a ramp velocity of 1% per second up to 10% strain 
and maintained at the position for 1800 s. The Young’s modulus was obtained from the 
equilibrium forces measured at 10% strain. 
Human mesenchymal stem cell cultivation and seeding 
Fresh bone marrow aspirates were obtained from Cambrex Life Sciences (East Rutherford, NJ), 
isolated and characterized as previously described [78]. Cells were expanded in high-glucose 
DMEM supplemented with 10% FBS, 1% pen-strep, and 0.1 ng/mL bFGF. The hMSCs were 
cultured up to the third passage and then used for seeding the scaffolds. The seeding process was 
previously described [87, 137]. In brief, scaffolds were seeded at the concentration of 30×106 
cells per 1 ml of scaffold. A 40-μl aliquot of cell suspension was pipetted onto blot-dried 
scaffolds and allowed to percolate through. The scaffolds were flipped 180° every 20 minutes 
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and 10 μl of media was added to prevent the cells from drying out. Constructs were cultured with 
osteogenic medium (low-glucose DMEM supplemented with 10% FBS, 10 nM dexamethasone, 
10 mM sodium-β-glycerophosphate, and 0.05 mM ascorbic acid-2-phosphate) for 3 days before 
insertion into the bioreactor.  
Bioreactor cultivation 
A perfusion bioreactor developed in our laboratory, as described and used previously [87, 204], 
was employed in this study. In brief, 6 scaffolds were placed in each bioreactor and medium flow 
rate was set to provide the superficial velocity of medium through the scaffolds at 400 μm/s. Half 
of the medium volume was replaced twice a week and scaffolds were harvested for analysis at 
week 5.  
DNA quantitation 
Constructs were cut in half in the longitudinal direction, washed in PBS and the wet weights 
were determined. For DNA analysis, the samples (n=8) were stored at -20°C in 1 ml of digestion 
buffer (10 mM Tris, 1mM EDTA and 0.1% Triton X-100) with 0.1 mg/ml of proteinase K in 
micro-centrifuge tubes. Samples were then thawed and maintained in this solution overnight at 
56°C to extract the DNA. The DNA content was determined using a Picogreen assay (Molecular 
Probes, OR). 
Histology and immunohistochemistry 
Constructs were washed in PBS, fixed in 10% formalin, embedded in paraffin, sectioned into 4 
μm slices and stained with haematoxylin and eosin (H&E), and Von Kossa. 
Immunohistochemistry staining for bone sialoprotein (BSP) was also conducted as previously 
described [87].  
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Statistical analysis 
Multiway Analysis of Variance (ANOVA) to analyze groups at the same time point and within 
group at different time points was carried out followed by Tukey’s post hoc analysis using 
STATISTICA software, with p<0.05 being considered as significant. 
 
Figure VI-1: Scanning electron microscopy of the silk sponge (A and B) and microparticle-
embeded silk sponge (C and D). Low magnification (A and C) shows the scaffold with similarly 
high porosity (Bar = 200 μm). High magnification (B and D) demonstrates the difference in the 
scaffold topography between the two groups (Bar =2 μm). The incorporation of silk 
microparticles (D and inset) increased surface roughness as compared to the silk sponge without 
microparticles (B). 
RESULTS 
Scanning electron microscopy 
Low magnification SEM indicated similarity in scaffold porosity and pore structure between SS 
and PS groups (Fig.VI-1 A and C). Greater detail of scaffold surface property was detected at 
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high magnification. The scaffold surface of SS was smooth while the surface of PS was much 
rougher (Fig.VI-1 B and D). SEM also showed incorporation of microparticles in silk scaffold 
(Fig.VI-1 D inlet) 
 
 
Figure VI-2: DNA contents after 5 weeks of cultivation for 16-0, 16-16, 32-16, and 32-0. 
Groups were not significantly different (3392±581, 2819±634, 3139±216, and 3072±309 ng per 
scaffold, respectively). 
Scaffold mechanical property 
Increasing silk fibroin concentration from 16 to 32 w/v % significantly increased the equilibrium 
compressive modulus (16-0 vs. 32-0 and 16-16 vs. 32-16, Table VI-1). Embedding silk 
microparticles into silk sponges also resulted in a significantly higher equilibrium compressive 
modulus compared to their respective SS group (16-0 vs. 16-16 and 32-0 vs. 32-16, Table 1).  
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Figure VI-3: Histomorphology of engineered human bone. Live/Dead confocal microscopy (top 
row), BSP (middle row), and Von Kossa staining (bottom row) of the four types of silk scaffolds 
after 5 weeks of cultivation. Arrow indicates matrix deposition at the internal scaffold surfaces. 
Scale bar: 400 μm. 
Tissue engineered bone construct 
After 5 weeks of culture, the DNA contents were similar in all study groups (Fig.VI-2). 
Live/dead assay displayed good cell viability in all four groups of scaffolds (Fig.VI-3). 
Histological analysis revealed that there were more cells at the periphery than in the central 
regions of the scaffolds. BSP (Fig.VI-3) were expressed in all four groups. In addition, calcium 
deposition detected by Von Kossa staining was observed for all groups (Fig.VI-3). Under high 
magnification, PS groups showed mineralization (Von Kossa) and matrix deposition (BSP) along 
the scaffold surface while no such evidence occurred in SS groups (Fig.VI-3, arrow). The 
increases in equilibrium Young’s modulus in the two PS groups were significantly higher than 
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their respective SS groups (Fig.VI-4). By comparing the effect of initial scaffold stiffness (16-0 
vs. 32-0 and 16-16 vs. 32-16), the Young’s modulus increased significantly (Fig.VI-4 blue box). 
In addition, when comparing on the effect of surface roughness (32-0 vs 16-16 groups), the 
Young’s modulus of the 16-16 group increased significantly more than the 32-0 group (Fig.VI-4 
yellow box)  
 
 
Figure VI-4: Increase in compressive equilibrium modulus after 5 weeks of cultivation. Blue 
and yellow box illustrates comparison on the effect of stiffness and roughness, respectively. Red 
and blue line indicates significant differences (p<0.05 and p<0.1, respectively). 
DISCUSSION 
In the present study, silk microparticles were incorporated into the silk matrix during processing 
to create a protein–protein composite. The ability to optimize the interfacial contact between the 
matrix and filler phases is critical to maximize the mechanical properties of a composite. For 
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example, if the reinforcing agent has superior mechanical properties but the interface between 
the filler and the matrix is weak, the composite will fail along the interface. Therefore, strong 
interfacial binding is essential to facilitate transfer of the mechanical load from the matrix to the 
reinforcing agent and vice versa [235]. 
In the present study, silk microparticles were incorporated into the silk matrix during solution 
processing. The inclusion of particles into silk solution with low silk concentration (16-0) and 
high silk concentration (32-0) increases equilibrium compressive modulus by approximately 6.6 
and 1.7 folds, respectively, (Table VI-1). The inclusion of particles allowed the constructs to 
approach the native trabecular bone (~10 MPa) [234] while maintaining scaffold structure and 
porosity (Fig.VI-1). These results suggest that an effective load transfer was achieved between 
the silk fibroin sponge matrix and the silk fibroin microparticle reinforcement, presumably due to 
the strong interfacial contact produced through solution processing. 
The study was designed to independently investigate the effects of scaffold stiffness (by 
comparison within the SS groups or within PS groups), and scaffold roughness (by comparison 
between the corresponding PS and SS groups). The changes in scaffold stiffness and surface 
roughness did not alter proliferative capabilities of the hMSCs (Fig.VI-2). Over 5 weeks of 
culture, hMSCs remained viable inside the scaffolds and differentiated into bone forming cells 
(Fig.VI-3). According to the histology and immunohistochemical staining, no significant 
differences were detected due to the initial stiffness on hMSC proliferation and differentiation 
amongst the different scaffolds (Fig.VI-3). However, live/dead analysis (Fig.VI-3) showed more 
cells were present on the scaffold surface of PS groups. The difference in concentration indicates 
better cell attachment and proliferation due to the surface roughness. The cell differentiation led 
to the deposition of BSP and mineral on the surface of the microparticle-embeded scaffolds 
(Fig.VI-3). On the other hand, BSP and mineral deposition on silk scaffolds without 
microparticles occurred only within the pore space. This trends was consistent with that 
suggested by many other studies [136, 137, 216]. With the localization of BSP and mineral 
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deposition, the mechanical property of the tissue-engineered constructs was enhanced. The 
compressive mechanical properties of the PS scaffolds significantly increased after culture when 
compared to their respective SS group (Fig.VI-4 red line). Furthermore, the mechanical property 
increased due to both the effect of initial stiffness and surface roughness (Fig.VI-4 blue and 
yellow box).   
It is not surprising that increasing the rigidity of the scaffold enhanced the differentiation of 
hMSCs into osteoblasts as defined by mineral deposition. Mechanical forces are known to be 
vital for wound healing and tissue homeostasis in adult organisms [236]. Matrix stiffening may 
increase cellular contractibility and matrix deposition. In addition, the role of matrix stiffness in 
cell motility and behavior has also been explored [237] and shown to influence differentiation. 
Particularly, hMSCs differentiate into an osteogenic lineage on stiffer substrates, whereas the 
cells appear more neurogenic on more compliant matrices [238]. While vast evidence has 
demonstrated the positive effect of substrate stiffness toward osteogenic differentiation and bone 
formation of hMSCs, the true effect of surface roughness is unknown. A previous study has 
suggested that surface roughness may play a role in stimulating hMSC osteogenic differentiation; 
however, the study was not able to decouple surface roughness from other effects such as 
chemical composition or scaffold stiffness [193]. This study successfully investigated the true 
effect of surface roughness in a silk sponge scaffold system. Results of the study show that 
surface roughness enhanced bone matrix deposition onto the scaffold surface, which resulted in 




Aim 1.3: Effect of Bone Sialoprotein on Cell-Mediated Collagen 
Mineralization 
INTRODUCTION 
Until recently, the process in which mineral crystals nucleation on non-collagenous proteins 
(NCP) bind to the collagen fibrils was believed to be the dominating mechanism for bone 
mineralization. New discoveries have proposed a detailed mechanism of mineralization of 
collagen fibrils [167, 168]. The studies showed that calcium-based biominerals could be formed 
via stable pre-nucleation clusters [239] with aggregation into an amorphous calcium phosphate 
(ACP) and subsequently, transformation of this phase into a crystal [240]. These findings 
suggested that collagen is an active scaffold for the formation of oriented hydroxyapatite 
platelets, with domains of charged amino acids in both the gap zone and the overlap zone acting 
as nucleation sites for crystalline hydroxyapatite. Interestingly, the mineralization of collagen 
fibrils in these studies contains no NCPs to initiate mineral formation. Instead, hydroxyapatite 
crystallization inhibitors, polyaspartic acid or fetuin, were employed to mimic the polyanionic 
character of the NCPs [165, 166].  
Bone sialoprotein (BSP) is one of the most important NCPs involved in bone mineralization. 
BSP is expressed nearly exclusively in mineralizing tissue [148]. The findings suggested that the 
BSP-mineral complex acts as a carrier for mineralizing collagen fibril. It can specifically bind to 
collagen via a 20 AA long domain. Furthermore, BSP can bind hydroxyapatite through two 
glutamic acid-rich regions, which are both required for its functional activity as a nucleator of 
hydroxyapatite [149]. In addition, it has been demonstrated that after treatment with 
organophosphate for 4-8 h, BSP localizes to the ECM in osteoblastic cultures, well before the 
first appearance of apatite crystals [51,58]. This suggests that inorganic phosphate triggers BSP 
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secretion into the ECM, where it can subsequently nucleate calcium phosphate in metastable 
solutions. In contrast, opposing findings suggested that bone sialoprotein is associated with a 
population of vesicle-like structures, defined as crystal ghosts, which are 500 – 800 nm in size 
prior to infiltration into collagen fibrils [145]. It is unknown as which of these mechanisms is 
dominant under cell-mediated collagen mineralization.  
Collagen mineralization by cells is a complex process. Cells must (i) produce collagen matrix, 
the platform for mineralized tissue, (ii) introduce metastable conditions of calcium and 
phosphate ions by releasing calcium and alkaline phosphatase to cleave organic phosphate 
molecules, and (iii) express and release NCPs such as BSP which play important roles in 
initiating mineral nucleation. However, the specific role of BSP in cell-mediated collagen 
mineralization is unclear. This study employed tissue-engineering techniques to study the effects 
of initial BSP in its native state on collagen mineralization by osteogenic progeny of human 
mesenchymal stem cells (hMSC).  
If the mechanism in which BSP binds to collagen fibrils prior to mineral nucleation is dominant, 
the pre-existing BSP in collagen matrix will enhance collagen mineralization by nucleating more 
minerals. However, if BSP binds to calcium phosphate ions prior to collagen infiltration, the pre-
existing BSP may not have any effect on collagen mineralization or could even inhibit the 
process by reducing the binding affinity of infiltrating BSP-mineral complex. We hypothesized 
that the presence of native BSP in bone collagen matrix would not enhance collagen 
mineralization, but rather inhibit MSC-mediated mineralization. The study employed the 
processing of bone matrix to preserve or remove BSP from native bone collagen matrix. 
Demineralized bone matrix (DBM) is a common clinically used bone graft due to its superior 
osteoinductivity and osteoconductivity. The process of bone demineralization removes cellular 
materials and mineral but preserves collagens and some NCP of the native bone structure, 
including BSP. Bone processing techniques to isolate BSP have been previously developed. 
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Cellular and other protein components not bound to the mineral phase can be extracted using 4M 
guanidine hydrochloride (GuHCl), prior to demineralization with 0.5 M EDTA [241, 242]. This 
process was applied on a variety of mineralized vertebrate tissues to isolate a number of other 
mineral-related phosphorylated NCPs [241, 243, 244]. A second dissociative extraction, after 
demineralization, was added to the protocol to remove tightly bound mineral-protected BSP 
molecules from the structural collagen matrix [242]. As a result, the native bone collagen matrix 
without BSP and other NCPs can be generated for the study. 
METHODS 
Scaffold preparation 
The process for scaffold preparation is illustrated previously (Ill.VII-1). Briefly, trabecular bone 
plugs (4 mm in diameter) were cored from the subchondral region of calf carpometacarpal joints. 
All solutions contained proteinase inhibitors consisting of 100 mM 6-amino-n-hexanoic acid, 5 
mM benzanidine hydrochloride, 5 mM N-ethylmaleimide, and 1 mM phenylmethane sulphonyl 
fluoride, in order to preserve protein function. Plugs were washed in water to remove marrow 
and rinsed in PBS with 0.1% ethylenediaminotetraacetic acid (EDTA) for 1 h at room 
temperature. This was followed by sequential washes in hypotonic buffer (10 mM Tris, 0.1% 
EDTA, pH 8.0), decellularizing solution (10 mM Tris, 0.1% EDTA, 0.5% Triton-X-100, 200 
rpm for 3 days). Decellularized bone plugs were rinsed in PBS, freeze-dried, and ground to yield 
cylinders of 4 mm in diameter and 2 mm thickness. Scaffolds of density between 0.29 to 0.42 
mg/μl were selected for the study. The scaffolds were washed in 2:1 chloroform:methanol (100 
mg scaffolds per ml solution) for 1 hr to remove additional fat and allowed to air dry overnight. 
All subsequent washes were conducted at 4°C. The scaffolds were washed in 4 M guanidine 
hydrochloride (GuHCl), and 50 mM Tris-HCl (20 mg scaffolds per ml solution) for 24 hours 
with one solution change. The scaffolds were washed twice in PBS, prior to demineralization in 
0.5 M EDTA in 50mM Tris-HCL (20 mg scaffolds per ml solution) for 36 hours with one 
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solution change at 24 hours. Following demineralization, the scaffolds were washed in PBS 
twice and split into two groups: (i) BSP+ and (ii) BSP-. For BSP+ scaffolds, PBS was used to 
sequentially wash the scaffolds. BSP- scaffolds were sequentially washed with strong detergent 
(4 M GuHCl, 50 mM Tris-HCl, 20 mg scaffolds per ml) to also remove BSP from the matrix, 
and washed with PBS twice. The scaffolds were sterilized in 70% ethanol for 2 days prior to cell 
seeding. 
 
Figure VII-1 Scaffolds fabrication process. 
Human mesenchymal stem cell culture and seeding 
Fresh bone marrow aspirates were obtained from Cambrex Life Sciences (East Rutherford, NJ). 
The cells were isolated and characterized as previously described [78]. Cells were expanded in 
high glucose DMEM supplemented with 10% FBS, 1% penicillin-streptomycin, and 0.1 ng/mL 
bFGF. Scaffolds were seeded with 7.5×105 passage 4 hMSC each (30×106 cells per ml tissue 
volume). Briefly, a 20 μl volume of cell suspension was added onto dry scaffolds and allowed to 
percolate through. The scaffolds were flipped every 20 minutes, and 5 μl of media was added 
each time to prevent the cells from drying. The seeded constructs were cultured in osteogenic 
media (low glucose DMEM supplemented with 10% FBS, 10 nM dexamethasone, 10 mM 
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sodium-β-glycerophosphate, 0.05 mM ascorbic acid-2-phosphate) for up to 5 weeks. Scaffolds 
(n=15) from each group were harvested at day 1 (D1), week 1 (W1), 3 (W3), and 5 (W5). 
Mechanical testing 
The equilibrium compressive Young’s modulus (n=4 per group) was measured under unconfined 
compression using a modification of an established protocol [103]. An initial tare load of 5 g was 
applied, followed by a stress-relaxation step in which specimens were compressed at a ramp 
velocity of 1% per second up to 10% strain and then maintained for 1800 s. The Young’s 
modulus was obtained from the equilibrium force measured at 10% strain. Mechanical properties 
of decellularized trabecular bovine bones were also measured with the same method. 
Biochemical assays 
Calcium quantitation was conducted on samples after mechanical testing (n=4), which were 
rapidly frozen in liquid nitrogen and stored at -20°C. Calcium was extracted in 500 μl of 5% 
TCA solution using a bead beater and analyzed with the Calcium (CPC) Liquicolor® kit 
(Stanbio Laboratory, USA). For DNA and alkaline phosphatase (ALP) quantitations (n=4), 
constructs were cut in half longitudinally, washed in PBS, and the wet weights were determined. 
For DNA analysis, the samples were stored at -20°C in 1 ml of digestion buffer (10 mM Tris, 
1mM EDTA, 0.1% Triton X-100) with 0.1 mg/ml proteinase K in microcentrifuge tubes. 
Samples were then thawed and maintained in this solution overnight at 56°C to extract the DNA. 
The DNA content was determined using the PicoGreen assay (Molecular Probes, OR). For ALP 
content analysis (n=4 halves), constructs were rapidly frozen in liquid nitrogen and stored at -
20°C. The ALP quantitation was conducted using the Sensolyte® pNPP Alkaline Phosphatase 




Samples from each group at each time point (n=4) were analyzed for Runx2, Col1a, BSP, OPN, 
and ON gene expression with quantitative PCR. Each gene was normalized by a housekeeping 
gene, GAPDH, and then normalized relative to BSP+ day 1 samples. 
Histology and Immunohistochemistry 
Constructs were washed in PBS and fixed in 10% formalin, then embedded in paraffin and 
sectioned into 8 μm slices, before staining with Alizarin Red S and Von Kossa to detect 
mineralized matrix.  
Statistical Analysis 
Multiway Analysis of Variance (ANOVA) was used to analyze groups at the same time point 
and within groups at different time points, followed by Tukey’s post-hoc analysis using 
STATISTICA software, with α=0.05. 
 
 
Figure VII-2: (A) DNA content per construct and (B) Scaffold equilibrium modulus for BSP+ 
and BSP- after cultivation for 1 day (D1), 1 week (W1), 3 weeks (W3), and 5 weeks (W5). 




Figure VII-3: Alizarin Red staining of calcium deposition on (A) BSP+ and (B) BSP- at 5 weeks 
of cultivation. (C) Calcium quantitation which corresponding to the Alizarin Red stain. There are 
no statistically significant differences between BSP+ and BSP- at all time point. *significantly 
different from the indicated time point (p<0.05). 
RESULTS 
Scaffold fabrication and tissue engineered bone property 
Demineralization removed mineral leaving behind protein approximately 30% of the 
decellularized bone dried weight. The demineralization process with EDTA maintained the 
original trabecular bone architecture. In addition, sequential washes with PBS or GuHCl did not 
alter the scaffold seeding efficiency [Fig.VII-2A] or mechanical properties [Fig.VII-2B]. The 
cell seeding efficiencies on BSP+ and BSP- matrix were not significantly different at 61.9±4.7% 
and 66.0±3.3%, respectively. hMSC-seeded BSP+ and BSP- scaffolds were cultured statically in 
osteogenic media for up to 5 weeks. Both DNA quantification and Young’s moduli measurement 
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Figure VII-4: Von Kossa staining of phosphate deposition on (A) BSP+ and (B) BSP-. The 
images selected were the most representative of the average fraction of mineralized collagen 
within the group (72.1% and 85.7% for BSP+ and BSP-, respectively). (C) Fraction of 
mineralized collagen obtained from image analysis of Von Kossa staining. (D) ALP per DNA for 
BSP+ and BSP- at different time points. #significantly different between BSP+ and BSP- 
(p<0.05). *significantly different from the indicated time point (p<0.05). 
Mineralization of collagen matrix 
Alizarin Red showed no calcium deposition at day 1 and week 1 and minimal calcium deposition 
inside collagen fibrils at 3 weeks of culture. Calcium fully occupied collagen fibrils at 5 weeks 
for both BSP+ and BSP- scaffolds [Fig.VII-3A,B]. Calcium quantitation [Fig.VII-3E] 
corresponded with the Alizarin Red stain. Calcium content at Day 1, Weeks 1, 3 and 5 were 
1.1±1.2, 1.2±0.6, 7.1±6.2, and 172.0±28.1 μg, respectively, for BSP+ and 0.4±0.3, 1.0±0.5, 
18.0±11.4, and 178.6±23.7, respectively, for BSP-. The calcium content was not significantly 
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different between groups at each time point. Von Kossa, which stains for phosphate, another 
component of bone mineral, revealed particulate staining inside collagen fibrils at 3 weeks, and 
positive staining occupying most of the collagen fibrils at 5 weeks of culture for both groups 
(Fig.VII-4A,B). Based on both the Alizarin Red and Von Kossa stains, the proportion of 
mineralized collagen consisting of both calcium and phosphate was determined using image 
analysis. There was no mineralized collagen present after 1 day and 1 week of culture. The 
fraction of mineralized collagen area for BSP+ and BSP- was not significantly different 
(0.004±0.008% and 3.5±4.0%, respectively) at week 3, but was significantly different 
(71.8±4.1% and 84.3±9.8%, respectively) at week 5 (FigVII-4C). ALP content at week 3 and 5 
was significantly higher in the BSP- group relative to the BSP+ (Fig.VII-4D). 
Osteogenic gene expression 
hMSCs differentiate into osteogenic lineage over 5 weeks of culture. Runx2 gene expression was 
similar between the two groups, such that expression was highest at day 1, lowest at week 1, and 
then gradually increased over the rest of the culture period (Fig.VII-5A). Col1A1 (Fig.VII-5B) 
and SPARC (Fig.VII-5C) gene expression were stable throughout the culture period. Increases 
in SPP1 gene expression in BSP+ relative to BSP- were detected at all time points, with a 
significant increase in expression for BSP+ at week 1 (Fig.VII-5D). Interestingly, BSP gene 
expression (Fig.VII-5E) significantly increased over time for both study groups after 3 weeks of 
culture; further, this increase was significantly higher in BSP+ compared to BSP- (fold increase 
of 89±6 vs. 30±6 at week 3, 591±87 vs. 309±146 at week 5 for BSP+ vs. BSP-).  
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Figure VII-5: Normalized (A) Runx2, (B) Col1A1, (C) SPARC, (D) SPP1, and (E) BSP 
osteogenic gene expression for BSP+ and BSP- at all time points. #significantly different 
between BSP+ and BSP- (p<0.05). *significantly different from the indicated time point 
(p<0.05). 
DISCUSSION 
Previous theories and findings illustrated that mineralization of bone occurred by either (i) 
precipitation of mineral or (ii) formation of ACP infiltrating collagen fibrils. The mechanisms of 
the two methods were distinctively different. The precipitation of mineral crystals was suggested 
to be induced by NCP, which act as an origin of nucleation. NCPs adhere to collagen fibrils, 
followed by mineral nucleating from the collagen-bound NCPs. In contrast, ACP consisting of 
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NCP and calcium phosphate minerals are created prior to infiltration into collagen fibrils. 
Although, BSP has been shown to undergo both mechanisms, the function of BSP in mineralized 
bone tissues is not clear. This study employed a tissue engineering approach to study the 
mechanism of cell-mediated collagen mineralization in native bone protein matrix in the 
presence of native BSP. 
Bone collagen matrix with (BSP+) and without (BSP-) native BSP was successfully produced 
while maintaining the original demineralized bone matrix architecture. Removing BSP from 
native bone protein matrix allowed the investigation of the effects of BSP and the mechanism of 
cell-mediated collagen mineralization in osteogenically-induced cells. Although BSP contains a 
classical integrin-binding motif (RGD) near the C-terminal, BSP+ did not play a significant role 
in hMSC attachment, as seeding efficiency was similar between BSP+ and BSP-. In addition, the 
presence of native BSP did not affect cell proliferation (Fig.VII-2). 
Over 5 weeks of cultivation, hMSCs differentiated into osteogenic lineage, as indicated by 
RUNX2 gene expression (Fig.VII-5A), which exhibited an increase after 1 week of culture. The 
high expression at day 1 was likely due to the rapid change caused by osteogenic media 
induction, which stimulated the hMSCs to initiate osteogenic differentiation. The hMSCs began 
producing bone matrix at 3 weeks, regardless of the presence of pre-existing BSP. Calcium and 
phosphate deposition were detected in bone collagen matrix after 3 weeks of culture. Alizarin 
Red, which stains for calcium deposition, was an indication of osteoid formation, or developing 
bone (Fig.VII-3). In contrast, Von Kossa, which stains for calcified bone but not osteoid, was an 
indication of mature, mineralized collagenous tissue (Fig.VII-4 A&B). Image analysis of Von 
Kossa staining suggested that more mineral crystallization occurred when BSP was not initially 
present in the scaffold, which was counterintuitive since BSP was previously suggested to 
initiate mineral formation (Fig.VII-4C). The fraction of mineralized collagen matrix was 
proportional to the increase in ALP production (Fig.VII-4D) and BSP expression (Fig.VII-5E). 
The results suggested that osteogenically differentiated hMSCs recognized the presence of BSP 
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in the collagen matrix. In the absence of native BSP in the collagen matrix, hMSCs expressed 
more BSP and produced more ALP in order to mineralize collagen fibrils. In contrast, when BSP 
was initially present, the hMSCs did not initiate the process to nucleate and mineralize these pre-
existing BSP. Furthermore, BSP expression and ALP production were reduced, indicating an 
inhibitory mechanism. Interestingly, osteopontin (SPP1) expression was increased in BSP+ at 
week 1 (Fig.VII-5D). Osteopontin has been implicated as an important factor in bone 
remodeling [245], and may play a role in anchoring osteoclasts to the mineral matrix of bone 
[246]. The results of this study suggested that the presence of BSP signal hMSCs to undergo 
matrix remodeling, rather than initiate mineralization. Collagen type I and SPARC expressions 
remained constant over the culture period (Fig.VII-5 B&C). The environment, with a large 
quantity of unmineralized collagen type I, did not require further collagen production. SPARC, 
an acidic cysteine-rich glycoprotein that plays a vital role in bone mineralization, cell-matrix 
interactions, and collagen binding, did not seem to be required in this cell-mediated collagen 
mineralization.  
The study suggested that collagen matrix devoid of BSP was a more favorable environment for 
cell-mediated collagen mineralization. The presence of BSP-bound collagen matrix neither 
initiated nor enhanced calcium phosphate deposition, but rather inhibited the mineralization 
process of osteogenically differentiated hMSCs. In addition, the enhancement of collagen 
mineralization in collagen matrix without BSP, as well as the inability for pre-existing BSP in 
collagen matrix to stimulate mineral formation, suggested that the infiltration of BSP-mineral 




Aim 2 Experimentation: Engineering articular cartilage using novel cell pellet 
compression technique 
INTRODUCTION 
Osteochondral tissue engineering has the potential to provide biological grafts for the repair of 
poorly healing or degenerated articular cartilage. Previous attempts to fabricate osteochondral 
grafts, consisting of articular cartilage interfaced with bone, employed clinically unfavorable 
primary chondrocytes [184, 185], while grafts fabricated from bone marrow stem cells lacked 
physiological mechanical properties [136, 137]. Though scaffold-free grafts have previously 
exhibited dense matrix structure, controlling graft size and shape has proven to be challenging 
[134, 184, 185]. Our study employed a novel technique to engineer osteochondral grafts with a 
scaffold-free cartilage layer, using human bone marrow-derived mesenchymal stem cells 
(hMSC) and decellularized bone scaffolds. With this approach, the hMSCs developed into 
physiologic-like articular cartilage tissue with excellent integration to subchondral bone. 
METHODS 
hMSC cultivation 
Fresh bone marrow aspirates were obtained from Cambrex Life Sciences (East Rutherford, NJ). 
The hMSC were isolated and characterized, as previously described [78]. Cells were expanded in 
high glucose DMEM supplemented with 10% FBS, 1% penicillin-streptomycin, and 0.1 ng/mL 
bFGF, up to passage 4. 
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Decellularized bone scaffolds 
Decellularized bone was obtained, as previously described [87]. Briefly, trabecular bone plugs (4 
mm in diameter) were cored from the subchondral region of carpometacarpal joints of 2-4 
month-old cows. The plugs were washed to remove marrow and rinsed in PBS with 0.1% 
ethylenediaminotetraacetic acid (EDTA) for 1 h at room temperature, followed by sequential 
washes in hypotonic buffer, detergent and enzymatic solution. Decellularized bone plugs were 
rinsed in PBS, freeze-dried, and cut to 5 mm in length, yielding cylinders of 4 mm in diameter × 
5 mm in height. The weights and dimensions of each plug were measured in order to calculate 
scaffold density, and scaffolds within the range of 0.30-0.40 mg/cm3 were used. Scaffolds were 
sterilized in 70% ethanol, washed in PBS, and incubated in expansion medium, prior to seeding 
cells. The distribution of bone scaffolds of different densities was randomized. 
 
 
Figure VIII-1. Osteochondral construct fabrication process. 
Osteochondral graft fabrication 
Fig.VIII-1 illustrated the novel pellet compression technique for producing osteochondral grafts. 
hMSCs were centrifuged to form pellets of 5×105 cells and cultured in chondrogenic media (high 
glucose DMEM supplemented with 10 ng/ml TGF-β3, 100 nM dexamethasone, 50 mg/ml 
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ascorbic acid-2-phosphate, 100 mg/ml sodium pyruvate, 40 mg/ml proline, 1% insulin, 
transferrin, and selenous acid (ITS)+ mix and 1% pencillin-streptomycin). Osteochondral 
constructs were fabricated using cell pellets pre-cultured for 3, 5, and 7 days. Decellularized 
trabecular bone cores (4 mm in diameter × 4 mm thickness), processed as previously described 
[134], were inserted into sterile PDMS rings (4 mm diameter × 4.5 mm thickness) containing 8 
cell pellets, such that the edge of the bone core was level with the PDMS ring, to produce a 
cartilage region of 500 μm thickness. The constructs were inverted to expose the cartilage region 
and cultured in chondrogenic medium with two medium changes weekly for 5 weeks.  
Biochemical assays 
Constructs (n=4) were washed in PBS. Three layers were separated from each construct: the 
cartilage layer above the edge of the bone scaffold; the 1 mm interface layer of the scaffold 
directly under the cartilage layer; and the subchondral bone layer consisting of the remainder of 
the scaffold. Samples were placed in digestion buffer (50 mM Tris-HCl, 1 mM EDTA, 50 mM 
iodoacetaminde, 10 μg/ml pepstatin, 0.5 mg/ml proteinase K), incubated at 60°C overnight, and 
centrifuged at 300×g for 5 min. The supernatants were used to measure DNA and GAG content 
using a PicoGreen assay and a 1,9-dimethylmethylene blue dye with chondroitin-6-sulfate as a 
standard, respectively.  
Mechanical testing 
The Young’s modulus (n=4) of cartilage was determined using unconfined compression. 
Scaffolds were placed in a chamber containing PBS and compressed at a low speed of 500 nm/s 
(~0.1%/s strain rate) to allow equilibration during ramping. The force was recorded, and the 
Young’s modulus was determined from the initial slope of the stress-strain curve.  Friction tests 
(n=4) were conducted to determine the lubricating properties of the articular cartilage surface 
using a previously described testing apparatus [247], and the protocol consisted of measuring the 
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time-dependent friction coefficient of the cartilage surface against smooth glass in PBS. A 
constant 50 g load was applied with a sliding velocity of 1 mm/s, for a total translation of 10 mm 
for 1800 seconds. The time-dependent friction coefficient was calculated from the ratio of the 
friction force to the normal force. The minimum and maximum friction coefficient, denoted as 
μmin and μmax, respectively, were reported. 
Histology and immunohistochemistry 
Samples were fixed in 4% formaldehyde, decalcified, dehydrated, embedded in paraffin, and 
sectioned to 8 μm. Cartilage formation was verified by overall histomorphology (H&E), and the 
presence of total collagen (Masson’s trichrome), GAG (Alcian blue), and Collagen Types I, II, 
and X (immunohistochemistry).  
RESULTS 
Pellet maturity 
Cells in chondrogenic media condensed into spherical pellets overnight after centrifugation. The 
cell pellets became smaller and denser within 5 days, as seen by H&E staining (Fig.VIII-2 A-C). 
Total hydroxyproline content and hydroxyproline per DNA, representing the amount of 
collagenous matrix, were significantly higher in day 7 pellets (Fig.VIII-2D&E). After 
compressing the pellets under decellularized bone scaffolds, the osteochondral constructs were 
successfully fabricated to obtain a cartilage layer of approximately 500 μm thickness, interfaced 
with decellularized bone cores (Fig.VIII-2F).  
Engineered articular cartilage 
After 5 weeks of culture, the constructs developed into articular cartilage-like tissue. All 
constructs contained cartilage regions above the edge of the subchondral bone with strong 
cartilage-bone interfaces. Interestingly, the mechanical properties of the cartilage approached 
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physiological values (Table VIII). The Young’s moduli of constructs fabricated from day 3 and 
5 pellets were significantly higher than those constructed from day 7 pellets. The friction 
coefficients of the engineered cartilage surface were on the same order of magnitude as 
physiological values. Similar to the Young’s modulus results, both μmin and μmax were 
significantly lower in constructs formed using day 7 pellets. Biochemical assays showed that 
DNA content in the cartilage layer was similar in all groups and was significantly higher than in 
the interface and subchondral bone regions (Fig.VIII-3A). The DNA content in the interface and 
subchondral bone regions of constructs from day 3 and 5 pellets were significantly higher than 
that of constructs from day 7 pellets. GAG content per construct wet weight also exhibited 
similar trends as shown in DNA content (Fig.VIII-3B). 
 
Figure VIII-2: H&E of (A) Day 3, (B) Day 5, and (C) Day 7 pellets (scale bar = 500 μm). 
Biochemical assays for (D) total hydroxyproline content and (E) hydroxyproline per DNA of 
pellets at different time points. (* significantly different from the other groups). (F) H&E of an 
osteochondral construct fabricated from Day 3 pellets after 1 day of culture (scale bar = 500 μm). 
The thick, extremely dense cell cartilage layer and the penetration of cells into the subchondral 
bone was produced 
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Table VIII: Mechanical properties of engineered articular cartilage 
Group Young’s modulus (kPa) µmin µmax 
Day 3 pellets 771±241 0.049±0.015 0.281±0.032 
Day 5 pellets 837±239 0.046±0.010 0.298±0.023 
Day 7 pellets 454±56* 0.066±0.015* 0.343±0.049* 
Histology and immunohistochemistry revealed the structure resembling articular cartilage 
(Fig.VIII-4). H&E and trichrome staining demonstrated a thick articular cartilage layer with a 
cellularized interface integrating with the subchondral bone. Cell lacunae in the cartilage layer 
were surrounded by matrix rich in GAG. The interface region contained markedly less GAG than 
the bulk of the cartilage tissue (Fig.VIII-3). Immunohistochemistry showed light staining of 
collagen type I, whereas collagen type II exhibited intensely positive staining at the surface, in 
the deep cartilage region and the interface region. Moderate collagen type X stain was also 
detected in the interface region and on differentiated hMSCs.  
 
Figure VIII-3: (A) DNA content and (B) GAG per wet weight of cartilage, interface, and 
subchondral layers after 5 weeks of cultivation. (lines indicated significant differences; p<0.05).  
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Figure VIII-4: Histology and immunohistochemistry of osteochondral constructs (of day 3 
pellets). Left to right: H&E, Masson’s trichrome, Alcian blue, Collagen Type I, Collagen Type 
II, and Collagen Type X. (Scale bar = 250 μm) 
DISCUSSION 
The compression of bone cores onto pellets in a confined space forced the pellets to fuse and 
penetrate into the subchondral bone. Over the course of in vitro culture, a dense cartilage layer 
and a well-developed cartilage-bone interface region formed. The hMSCs differentiated along 
the chondrogenic lineage and produced chondrogenic extracellular matrix, forming a cartilage 
layer integrated with subchondral bone. The constructs formed from day 7 pellets exhibited 
inferior properties compared to constructs from day 3 and day 5 pellets for all analyses. 
Histology and biochemical assays dictated that day 7 pellets were more mature and denser than 
pellets from day 3 and day 5. As such, day 7 pellets may not fuse or penetrate into subchondral 
bone well, resulting in a less continuous structure than constructs fabricated with less mature 
pellets from day 3 and 5.  
Quantitation of DNA content and GAG per wet weight after culture confirmed the results. The 
interface and subchondral bone regions of constructs from day 3 and 5 pellets contain 
significantly greater cellularity that constructs from day 7 pellets, suggesting that less mature 
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pellets penetrate into subchondral bone more than the mature pellets. More GAG production also 
occurred at the interface, as a result of the differences in cellularity. The inferior ability of mature 
pellets to fuse together and integrate into subchondral bone resulted in constructs with poorer 
functional properties. 
Articular cartilage engineered using the pellet compression technique exhibits similar structure to 
native tissue, with cells in deep zone cartilage demonstrating lacunae-like morphology and cells 
at the superficial zone appearing flat and aligned. The two extracellular matrix proteins, collagen 
and GAG, which play great roles in cartilage function, were deposited in the desired regions, i.e., 
collagen was predominantly present in the superficial zone whereas dense GAG matrix was 
present in the deep zone. High production of collagen type II in the cartilage layer indicates 
successful hyaline cartilage development. The interface region contained extracellular matrix 
providing strong anchorage to the subchondral bone. Collagen type X, a hypertrophic cartilage 
marker, has been reported in chondrogenic MSC cultures [248]. Interestingly, the expression of 
collagen type X in the interface region further indicates strong integration between cartilage and 
subchondral bone.  
By using the pellet compression technique, we were able to produce osteochondral constructs 
with cartilage layers that are thicker than any previous scaffold-free fabrication technique 
reported thus far [185]. Most strikingly, this technique produced osteochondral constructs with 
physiologic mechanical properties. The mechanical Young’s moduli of the constructs 
approached 1 MPa, a value measured for young bovine articular cartilage. Notably, such a high 
compressive stiffness has not been previously accomplished by any method of cartilage tissue 
engineering using adult human mesenchymal stem cells. In addition, the surface lubrication 
properties of the engineered constructs were also similar to the values previously reported for 
native cartilage. [247, 249]  
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In conclusion, the pellet compression technique using immature hMSC pellets with 
decellularized bone scaffolds provides a platform for the development of native-like engineered 
cartilage within osteochondral grafts. The method successfully fabricated osteochondral grafts 






Aim 3 Experimentation: Spatial regulation of human mesenchymal stem cell 
differentiation in engineered osteochondral constructs: effects of pre-
differentiation, soluble factors and medium perfusion 
INTRODUCTION 
One method of the treatment of cartilage injuries is to replace the full-thickness defects with 
osteochondral plugs, where the bony region anchors the graft and facilitates the integration of the 
cartilage graft with the host tissue [250]. This approach is limited by insufficient availability of 
autograft material, donor site morbidity and the risks of disease-transmission associated with the 
allografts. To alleviate these limitations, it is possible to engineer biological replacements of 
cartilage and bone tissues using multi-potent human mesenchymal stem cells (hMSCs). There 
are, however, some inherent technical and scientific challenges to growing osteochondral 
constructs from hMSCs where bone and cartilage should ideally develop in tandem to facilitate 
functional integration of the two tissues. Most importantly, spatial regulation of hMSC 
differentiation is necessary to guide hMSCs down the chondrogenic or osteoblastic lineages in 
vitro and generate discrete cartilaginous and osseous regions within a single construct. 
Previously, hMSCs were separately differentiated into bone and cartilage constructs before 
physically opposing and suturing these constructs into biphasic units [136]. This approach 
required considerable manipulation of cultured tissues under sterile conditions and resulted in 
poor integration between the two tissue constructs. An alternative approach exposed the mouse 
MSCs to chondrogenic or osteogenic supplements during their monolayer expansion, and 
sequentially encapsulated the cells in gel substrates to create two distinct but contiguous 
constructs [135, 251, 252]. After 12 weeks in the dorsum of nude mice, the bone and cartilage 
remained grossly distinct with apparent regions of integration at the interface. While these results 
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are clearly promising, the use of in vivo mouse cultivation limits the clinical utility of these 
constructs. A distinct ‘pre-induction’ method has also been reported for hMSCs [134]. The 
resulting composites were cultured in a medium containing a cocktail of osteogenic and 
chondrogenic supplements for another 5 weeks. Encouraging results for bone-cartilage 
integration were achieved in this study with the main drawback being the long (10 weeks) 
cultivation times.  
Bioreactors can be utilized to provide biophysical stimulation and improved nutrient transfer to 
the cells on scaffolds, and enhance their functional assembly into tissues. Several bioreactor 
designs have been used for engineering bone [90, 137, 253] and cartilage [183, 254] from 
hMSCs. Most recently, we utilized a perfusion bioreactor for the cultivation of bone constructs 
[87]. The interstitial flow facilitated cell growth and differentiation, leading to the deposition of 
mineral and extracellular matrix (ECM) proteins throughout the bone region. We adapted this 
perfusion bioreactor for use in the present study. 
For scaffold materials, we selected those shown to be optimal in previous studies of cartilage and 
bone tissue engineering. Agarose gel was used for the cartilage phase, as it has been 
demonstrated that it yields the best mechanical properties of engineered cartilage among all 
materials studied with immature chondrocytes [103]. Likewise, decellularized bone was selected 
as a scaffold for the bone region, as it provides osteo-inductive architecture, mechanical 
properties and biochemical composition [201, 255]. Additionally, in our numerous previous 
studies, agarose and decellularized bone were used independently and in combination as 
scaffolds for cartilage, bone and osteochondral constructs [256, 257]. Therefore, we 
hypothesized that the agarose-bone scaffolds, alone or in combination with molecular and 
cellular parameters and biophysical stimuli, could provide hMSCs with differential cues 
necessary to induce spatially confined chondrogenesis (in agarose) and osteogenesis (in bone) 
while facilitating interfacial communication between the two developing tissues. To test this 
hypothesis, we explored the effects of three sets of experimental variables on hMSC 
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differentiation in biphasic constructs: (1) supplementation of chondrogenic factors vs a cocktail 
of chondrogenic and osteogenic factors, (2) pre-differentiation of hMSCs, (3) medium perfusion 
(interstitial flow). 
MATERIALS AND METHODS 
hMSCs cultivation and pre-differentiation 
Cryopreserved passage 2 bone-marrow derived hMSCs were kindly provided by Dr Caplan, after 
isolation using previously described protocols [258]. Cells were expanded for one passage (P3) 
in control medium (low glucose Dulbecco's Modified Eagle Medium (DMEM) supplemented 
with 10% Fetal Bovine Serum (FBS), 1 ng/ml Fibroblast Growth Factor (FGF) and 1% 
antibiotics). Passage 4 cells were split into three groups, and cultured for one more passage (8±1 
days) in (1) control medium (undifferentiated hMSCs), osteogenic medium (osteo-induced 
hMSCs), and chondrogenic medium (chondro-induced hMSCs). Undifferentiated and osteo- 
induced hMSCs were plated at a density of 5000 cells/cm2 while the chondro-induced hMSCs 
were plated at 60,000 cells/cm2 [259, 260]. Osteogenic medium was low glucose DMEM 
supplemented with 10% FBS, 1% antibiotics, 10 mM sodium-β-glycerophosphate, 100 nM 
dexamethasone, and 50 mg/ml ascorbic acid-2-phosphate. Chondrogenic medium was high 
glucose DMEM supplemented with 10 ng/ml Transforming Growth Factor-beta 3, 100 nM 
dexamethasone, 50 mg/ml ascorbic acid-2-phosphate, 100 mg/ml sodium pyruvate, 40 mg/ml 
proline, 1% Insulin, transferrin, sodium selenite (ITS)+ mix and 1% antibiotics. Passage 4 cells 
were then used for experiments. 
Pellet culture 
Cells cultured under the various conditions were resuspended in a specific medium 
(undifferentiated, osteo-induced and chondro-induced), counted, and 2.5×105 cells per aliquot 
were centrifuged to form pellets. Pellets from each group were then cultured in control, 
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osteogenic, and chondrogenic medium, resulting in 9 different conditions. Three pellets for each 
condition were cultured for 4 weeks in 1 ml of culture medium, with medium change three times 
per week. 
Decellularized bone scaffolds 
Decellularized bone was obtained as previously described [87]. In brief, trabecular bone plugs (4 
mm in diameter) were cored from the subchondral region of carpometacarpal joints of 2-4-
month- old cows. They were washed to remove marrow and rinsed in PBS with 0.1% 
ethylenediaminotetraacetic acid (EDTA) for 1 h at room temperature. This was followed by 
sequential washes in hypotonic buffer, detergent and enzymatic solution. Decellularized bone 
plugs were rinsed in PBS, freeze-dried, and cut to 5 mm lengths to yield cylinders 4 mm 
diameter × 5 mm high. The weights and dimensions of each plug were measured and used to 
calculate scaffold density. Scaffolds within the range of 0.30-0.40 mg/cm3 were used. Scaffolds 
were sterilized in 70% ethanol, washed in PBS and incubated in culture medium prior to seeding 
cells. The distribution of bone scaffolds with different densities was randomized. 
Biphasic scaffolds 
Bone scaffolds were seeded as previously described [87]. In brief, scaffolds were blot-dried and 
seeded with 1.8×106 cells suspended in 40 ml of media (45×106 cells/ml). The scaffolds were 
flipped every half hour and 10 ml media were added. After 2 h, 5 ml of media were added and 
scaffolds were incubated overnight. Agarose gels were made the following day by mixing equal 
volumes of 4% agarose solution and cell suspension to yield 25×106 cells/ml in 2% agarose. This 
was pipetted into cylindrical wells (4 mm  × 2.5 mm height) in PDMS molds. Bone scaffolds 
seeded on the previous day were overlaid allowing a penetration depth of 500 mm of gel into the 
bone scaffold. The agarose was then allowed to solidify at room temperature to complete the 
 92 
formation of biphasic constructs. The seeded scaffolds were cultured for 4 days under static 
conditions to allow cell attachment, prior to applying medium perfusion. 
 
Figure IX-1. Experimental design. (A) Biphasic scaffold made by interfacing agarose and 
trabecular bone scaffolds. (B) Perfusion bioreactor for cultivation of biphasic scaffolds. Enlarged 
view shows predicted path of medium flow through the scaffolds and through the sides into the 
reservoir. (C) Schematic of experimental design. 
Perfusion bioreactor 
A perfusion bioreactor developed in our laboratory and described previously [87] was used for 
cultivating biphasic tissue constructs. The constructs were positioned with the bone region 
secured in wells and agarose region in the reservoir. The bone region protruded 1 mm from the 
well. Culture medium was pumped axially upwards through the interstices of the bone region, 
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and out into the medium reservoir. The agarose region was completely submerged in culture 
medium in the reservoir, and was not perfused (Fig.IX-1B). The medium flowed through the 
bone scaffolds at a superficial velocity of 400 μm/s [87]. 
Experimental design 
The experiment was set-up to test the effects of three distinct variables: cell pre-differentiation, 
medium perfusion and medium supplements (Fig.IX-1C). To evaluate the influence of cell pre- 
differentiation, constructs were made from undifferentiated hMSCs (UD) or hMSCs pre-
differentiated to chondrocytes and osteoblasts (PD). To evaluate the effects of perfusion, each of 
the cell groups was cultured either in perfused bioreactor (BR) or statically (S). To evaluate the 
effects of medium supplements, each of the cell-bioreactor groups was cultured in either 
chondrogenic (C) or cocktail (Ck) medium (high glucose DMEM containing both chondrogenic 
and osteogenic supplements: 10% FBS, 10mM sodium-b-glycerophosphate, 100 nM 
dexamethasone, 50 mg/ml ascorbic acid-2-phosphate, 10 ng/ml TGF-β3, 100 mg/ml sodium 
pyruvate, 40 mg/ml proline, 1% ITS+ mix and 1% antibiotics). As a result, we obtained six 
experimental groups as shown in (Fig.IX-1C). This way, the effects of cell pre-differentiation 
were compared for two culture conditions and two sets of medium supplements (UD-BR-C/Ck 
vs PD-BR-C/Ck). Likewise, the effects of biophysical stimulation via medium perfusion were 
determined for both differentiated and undifferentiated cells, and both media compositions (UD-
S-C/Ck vs UD-BR-C/Ck). Finally, chondrogenic medium (which already contained 
dexamethasone and ascorbic acid) and the cocktail medium (containing additional osteogenic 
supplements) were compared for both cell groups and both sets of culture conditions (UD/PD-
BR-C vs UD/PD-BR-Ck). Data were obtained in two independent series of experiments. 
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Micro computerized tomography (μ-CT) 
μ-CT imaging was performed using a modified protocol from Liu et al. [208]. Constructs were 
aligned along their axial direction in a 15 ml centrifuge tube and stabilized with wet gauze. The 
tube was clamped in the specimen holder of a vivaCT 40 system (SCANCO Medical AG, 
Basserdorf, Switzerland). Constructs were scanned at 21 mm isotropic resolution, and the bone 
volume (BV) was obtained by global thresholding technique that detected only the mineralized 
tissue. 
Mechanical testing 
The equilibrium Young's modulus of the cartilage region was measured in unconfined 
compression using a modification of an established protocol [103]. An initial tare load of 0.02 N 
was applied. This was followed by a stress-relaxation step where the specimens were compressed 
to 10% strain of the cartilage region at a ramp velocity of 0.05%/s and maintained at that position 
for 1800 s. The Young's modulus was calculated from the equilibrium forces measured at 10% 
strain. 
Biochemical assays 
The gel and bone regions of three constructs per group were separated along the flat surface of 
the bone scaffold and the wet weight of the gel and bone regions determined. The samples were 
stored at 20°C. until assay. For analysis, the gel regions were digested in 1 ml proteinase K 
solution at 50°C. The bone regions were placed in 100 ml of proteinase K digestion buffer at 
50°C. DNA content was determined using the Picogreen assay (Molecular Probes, OR). The 
sulfated GAG (s-GAG) content of the extracts was determined using the 1,9-dimethylmethylene 




Figure IX-2. Cell differentiation studies. (A-C) Morphology of hMSCs cultured using (A) 
expansion medium, (B) osteogenic supplements and (C) chondrogenic supplements. (D-F) Von 
Kossa staining of pellets cultured under osteogenic conditions for 4 weeks. (G-I) Alcian Blue 
staining of pellets cultured under chondrogenic conditions for 4 weeks. 
Histology and immunohistochemistry 
Constructs were washed in PBS and fixed in 10% formalin, decalcified with Immunocal 
solution, embedded in paraffin, sectioned into 5 mm slices and stained with haematoxylin and 
eosin (H&E) and Alcian Blue (GAG). Samples were also immunohistochemically stained for 
collagens I and II and bone sialoprotein (BSP) as previously described[87]. 
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Statistical analysis 
Pair-wise comparisons of results were carried out using multi- way Analysis of Variance 
(ANOVA) followed by Tukey's post hoc analysis using STATISTICA software. P<0.05 was 
considered as significant. 
 
 
Figure IX-3. Quantitative properties of cartilage region. (A) GAG content of gels normalized by 
wet weight. (B) Equilibrium modulus. (C) DNA content normalized by wet weight. (D) BV of 
gels measured by μCT. (n 1⁄4 3; *P < 0.05; **P < 0.001) (E) Table of GAG expression and 
equilibrium modulus values normalized to DNA (n 1⁄4 3; *P < 0.05 as compared to the 
experimental groups using the same culture medium). 
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RESULTS 
Characterization of undifferentiated and pre-differentiated hMSCs 
Undifferentiated hMSCs maintained their fibroblast-like morphologies throughout the two-
dimensional (2D) cultivation period while osteo-induced hMSCs grew faster and appeared 
thinner but less elongated and less aligned to each other. Despite the high seeding densities and 
chondro-inductive medium, hMSCs were unable to adopt a spherical morphology, instead 
becoming broad and flat (Fig.IX-2 A-C). Pre-differentiation of hMSCs by 1-week monolayer 
cultivation in chondrogenic or osteogenic medium did not improve their subsequent three-
dimensional (3D) differentiation along the same lineage (osteo/osteo or chondro/chondro) during 
pellet culture (Fig.IX-2 D-I). Under osteogenic conditions, pellets from all three groups stained 
positively for mineral deposition (Fig.IX-2D,F) and expressed BSP (not shown). Under 
chondrogenic conditions, pellets from all three groups expressed GAG and formed lacunar 
structures. Both osteogenic and chondrogenic pre-differentiation appeared to decrease their 
subsequent chondrogenic potential in pellet culture relative to undifferentiated hMSCs. Pellets 
formed by undifferentiated hMSCs were approximately twice the size of those in other groups, 
and stained more intensely for GAG (Fig.IX-2G-I) and collagen type II (not shown). 
Cartilage region in biphasic constructs 
The highest GAG contents (expressed as a fraction of wet weight) were achieved for UD-S-C 
constructs (Fig.IX-3A). Biochemical and mechanical properties of engineered cartilage were 
significantly affected by the combination of cocktail medium and perfusion, but not by either 
stimulus alone. For example, GAG content was statis- tically similar when comparing UD-S-C 
(P 1⁄4 0.61%), UD-BR-C (P 1⁄4 0.59%) and UD-S-Ck (P 1⁄4 0.53%) constructs but there was a 
decrease in GAG contents for UD-BR-Ck group (P 1⁄4 0.02%) where both bioreactor cultivation 
and cocktail medium were used. Pre-differentiated hMSCs did not express significant quantities 
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of GAG (<0.1%). The equilibrium Young's modulus values reflected the trend of the GAG 
content [Fig. 3(B)]. Similar values were obtained for UD- S-C (18 kPa), UD-BR-C (22 kPa) and 
UD-S-Ck (15 kPa) while the modulus of UD-BR-Ck, PD-BR-C and PD-BR-Ck were all less 
than 10 kPa. The normalized DNA values were consistent with these findings as the DNA 
contents of UD-S-C, UD-BR-C and UD-S-Ck were approximately three times higher than the 
other three groups (Fig.IX-3C). It should be pointed out that the trend for GAG content 
remained the same when normalized to DNA content, but the differences observed between 
groups for equilibrium modulus disappears. μ-CT data indicated mineral deposition in the gel 
regions of UD-S-Ck and UD-BR-Ck groups only [Fig. 3D (inset)]. 
 
 
Figure IX-4. Representative images of immunohistochemical properties of cartilage region. First 
row: H&E staining. Second row: Alcian Blue staining for GAG content. Third row: collagen II 
expression. Fourth row: collagen expression. Fifth row: BSP expression. 
H&E staining indicated differences in cell distributions throughout the gel regions between the 
experimental groups. Under static conditions (UD-S-C and UD-S-Ck), the central regions closer 
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to the bony substrates were less densely populated than the edges, an effect that can be attributed 
to the diffusional limitations of nutrient transport (Fig.IX-4, first row). This pattern was less 
pronounced for the UD-BR groups (UD-BRC and UD-BRCk) where medium was perfused 
directly into the lower face of the gel construct. Decreased matrix deposition was again evident 
in PD-BR constructs (PD-BR-C and PD-BR-Ck). 
 
 
Figure IX-5. Representative images of immunohistochemical properties of bone region. First 
row: H&E staining. Second row: Alcian Blue staining for GAG content. Third row: collagen I 
expression in gels. Fourth row: BSP expression. 
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Bone region in biphasic constructs 
Quantitative evaluation of DNA content within the bone region of the constructs demonstrated 
little variation between the experimental groups (data not shown). The large variability in initial 
mineral content (obtained from m-CT) made it difficult to rigorously evaluate relative changes in 
mineralization based on cultivation conditions. However, histological analysis showed 
interesting effects of cultivation conditions on the properties of bone regions. H&E staining 
demonstrated that constructs cultured under static conditions resulted in cell growth and matrix 
deposition up to approximately 1 mm from the periphery of the bone scaffolds leaving the 
central regions largely unpopulated. In contrast, medium perfusion resulted in more uniform cell 
distribution and matrix accumulation throughout the pore spaces of the bone scaffolds (Fig.IX-5, 
first row). GAG deposition was evident for undifferentiated cells cultivated in chondrogenic 
medium (Un-S-C and Un-BR-C), and rather low in the groups cultivated in cocktail medium. 
Again, the combined effects of perfusion and cocktail medium were evident: Un-S-Ck groups 
also showed patches of light GAG staining while the Un-BR-Ck groups showed no GAG 
staining (Fig.IX-5, second row). 
Osteogenic pre-differentiation alone was not sufficient to eliminate chondrogenic differentiation 
in the bone region: PD-BR-C showed light GAG staining, but this was eliminated in the presence 
of osteogenic supplements (PD-BR-Ck group). Undifferentiated groups cultured in chondrogenic 
medium (Un-S-C and Un-BR-C) did not exhibit collagen I or BSP staining. Interestingly, the 
pre-induced osteoblasts cultured in chondrogenic medium (PD-BR-C) expressed BSP and 
collagen I throughout the scaffold. Cocktail supplements without flow were sufficient to elicit 
minimal BSP expression (Un-S-Ck), but the expression of BSP and collagen I increased with 
perfusion (Un-BR-Ck and PD-BR-Ck) (Fig.IX-5, third and fourth rows). 
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Figure IX-6. Integration of bone and cartilage regions. (A) Integration region of static constructs 
(UD-S-C) is mostly acellular. (B) High magnification image of region indicated by box in (A) 
showing different morphologies in gel and scaffold regions and minimal GAG expression. (C) 
Integration between cartilage and bone is enhanced under bioreactor conditions. (D) High 
magnification image of region indicated by box in (C) shows high matrix production in central 
regions of integration zone. Distinct spherical morphology in gel is indicated by * whereas the 
elongated, fibrous morphology is evident in regions close to bone by arrows ([). 
Integration of cartilage and bone regions 
The integration in the region where agarose gel penetrated into the porous bone scaffold was 
assessed by examining the properties of cell and tissue matrix. Constructs cultured under static 
condi- tions demonstrated the presence of cells only at the outer edges of the integration zone 
(Fig.IX-6A) but no cells were observed in the inner regions (Fig.IX-6 A,B). To evaluate the 
effect of perfusion on integration, the integration zone for the Alcian Blue-stained Un-BR-C 
construct is shown in Fig.IX-6C. Cells were present throughout the integration zone in these 
constructs. Interestingly, while cells throughout the entire region are expressing GAG, indicative 
of chondrogenic differentiation, there is evidence of morphological differences. Cells embedded 
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completely within the agarose gel are spherical and reside within lacunae, while cells within 
close proximity to the bone scaffold exhibit more fibrous morphologies (Fig.IX-6D). It was 
noted that the fibrous regions did not form as a uniformly horizontal layer throughout the 
integration zone hence there was no evidence of a discrete layer separating bone from cartilage. 
DISCUSSION 
Early tissue engineering studies investigated the feasibility of forming osteochondral constructs 
from two separate regions containing differentiated chondrocytes and osteoblasts, and using the 
resulting composites for the repair of focal defects [261, 262]. However, differentiated cells do 
not provide a practical clinical option as they are limited in supply, their harvest is associated 
with morbidity and the danger of secondary joint disease, and it is difficult to procure healthy 
cells for therapeutic use. One attractive cell source for cartilage and bone tissue engineering is 
hMSCs because of their innate capability to make osteochondral tissues. Numerous reports have 
demonstrated the feasibility of growing either bone-like or cartilage-like tissues from hMSCs, 
although the functional outcomes for cartilage have never been comparable to those ach- ieved 
using immature chondrocytes. Still, growing ‘complex’ tissues is dependent upon the ability to 
provide the hMSCs with the appropriate chondrogenic or osteogenic cues in a site-specific 
manner. Therefore, the primary objective of our study was to evaluate various experimental 
conditions which could enable the simultaneous development of integrated, yet distinct, bone and 
cartilage tissues from a homogenous hMSC population. 
hMSC pre-differentiation reduces subsequent chondrogenesis 
We tested the hypothesis that pre-differentiating the cells would turn on lineage-specific genes, 
expedite the formation of cartilage and bone regions within the osteochondral plugs and 
predispose cells to respond to either osteogenic or chondrogenic stimuli in cocktail medium, but 
not both. The results of pellet culture experiments, which were used to determine the 
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stability of cells after differentiation, demonstrated that pre-differentiated hMSCs could still 
respond to opposing stimuli even though the effect was attenuated relative to undifferentiated 
hMSCs (Fig.IX-2). It was also found somewhat counter- intuitively that the chondrogenic pre-
differentiation reduced the hMSCs’ potential to form cartilage matrix in 3D culture. A similar 
approach was taken and shown to be successful using rat MSCs. This difference may reflect an 
inherent distinction in the capacity of rat vs human cells under similar cultivation conditions. In 
retrospect, this is not surprising, because the chondrogenic potential of hMSCs is heavily 
dependent upon their ability to maintain a spherical morphology [200]. By providing 
chondrogenic stimuli during monolayer culture, the cells were essentially presented with 
conflicting stimuli, which negatively affected subsequent development. 
Chondrogenesis is reduced by the combination of flow and cocktail medium 
Undifferentiated hMSCs cultured statically in agarose gels (UD-S-C) produced 0.6% GAG and 
had Young's moduli of approximately 20 kPa. These values are considerably lower than those 
observed for constructs grown with immature bovine chondrocytes [106], but are in the range of 
values reported for bovine MSCs [183]. These results underscore the inherent difficulty in 
elucidating and providing the appropriate cues for directing stem cells into mature chondrocytes 
in vitro. Yet, the scaffold-bioreactor system provided critical insights into the ability of hMSCs 
to integrate multiple stimuli in cell-fate decisions. Notably, relative to the UD-S-C group, 
changing to perfusion only (Un-BR-C) or cocktail medium only (UD-S-Ck) had no significant 
effect on tissue composition content and mechanical stiffness, while both param- eters were 
negatively affected by the combination of cocktail medium and perfusion (UD-BR-Ck) (Fig.IX-
3). Collagen X stains (Fig.IX-4) suggested hypertrophy of hMSC-derived chondrocytes in all 
groups where undifferentiated hMSCs were used to form the cartilage layer, with the strongest 
expression in the cultures where cocktail medium was used. This is consistent with the notion 
that hypertrophy is generally associated with MSC chondrogenesis. 
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Pre-differentiation, flow and cocktail medium provide the best osteogenic conditions 
Our study tested whether the biochemical environment of trabecular bone matrix combined with 
flow-induced shear stress through the constructs may have been sufficiently osteo-inductive for 
new bone formation. It was evident that the soluble factors in the medium had the most potent 
effects on cell differentiation: extensive GAG and collagen II staining were evident throughout 
the bone regions of UD-S-C and UD-BR-C groups (Fig.IX-5) indicating that the combination of 
flow and the trabecular bone biochemistry was insufficient for osteogenesis. Cells in the scaffold 
did, however, appear to be predisposed to an osteogenic phenotype since cultivation in cocktail 
medium (UD-S-Ck and UD-BR-Ck) virtually eliminated GAG and collagen II staining while 
upregulating BSP expression. Perfusion considerably improved cell distribution throughout the 
bone regions of the constructs (Fig.IX-5). There was also decreased collagen II and increased 
BSP expression in the UD-BR-Ck relative to UD-S-Ck groups indicating flow might play a role 
in further stimulating osteogenesis of hMSCs at the expense of chondrogenesis. However, further 
investigations are required to elucidate whether it is due to biophysical stimulation or improved 
cell-cell communication associated with high cell densities. 
Spatial regulation of hMSC differentiation and bone-cartilage integration 
In this study we have explored the combination of in vitro culture conditions that give rise to 
suitable chondrogenic or osteogenic differentiation of hMSCs in pre-determined regions of 
osteochondral constructs. Static culture of undifferentiated hMSCs in chondrogenic medium 
elicited the best cartilage properties while perfusion culture of pre-differentiated osteoblasts or 
undifferentiated hMSCs with cocktail medium provided the best osteogenic response. 
The collected data support the notion that an osteochondral bioreactor should contain two 
discrete compartments [263, 264], which would enable cells in either region to be exposed to 
optimal stimuli, including different medium compositions. In comparison to the previous in vitro 
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studies [134, 136], we used an experimental design that allowed the cartilage and bone phases to 
develop in tandem. The interface formed in biphasic constructs remains different from that in a 
native issue where the bone cartilage cross-talk occurs at a clearly demarcated zone of 
mineralized cartilage. Future studies may focus on clarifying the conditions required to 
recapitulate the native interface and investigating the heterogenous cell-cell communication in 
this region. It is also interesting to note that the gel region of this group (UD-BR-Ck) constructs 
strongly expressed GAG (Fig.IX-3A) while simultaneously depositing considerable amounts of 
mineral (Fig.IX-3D). Future studies may determine whether hMSCs are capable of expressing 
the osteogenic and chondrogenic phenotypes simultaneously similar to the immature cell 
phenotype which exists during intramembranous ossification [4] or whether these are two 
distinct populations which co-exist in the gel regions. Such studies may provide insight into 
mechanisms of stem cell differentiation and cellular interactions at the osteochondral interface. 
In conclusion, the study demonstrated the feasibility of engineering biphasic tissue constructs 
using biphasic scaffolds and perfusion bioreactors enabling spatial regulation of hMSC 
differentiation. Pre-differentiation of hMSCs in monolayer culture was beneficial for bone tissue 
development but not cartilage. It was shown that undifferentiated hMSCs are capable of 
integrating signals from biological factors and perfusion stimuli into decisions to differentiate 
into chondrocytes or osteoblasts, and perfusion culture considerably enhanced tissue 
development and improved integration of bone and cartilage tissues. Future studies will focus on 
the development of an osteochondral bioreactor, and the facilitation of the biological 




Personalized Osteochondral Bioreactor for Engineering TMJ Condyle 
Regeneration of the normal shape, architecture, and function of tissues following congenital 
abnormality, trauma, or surgical treatment presents special problems to tissue engineering. 
Because of the great variation in properties of these tissues, currently available treatment options 
fall short of adequate care. The engineering of personalized grafts customized to the patient 
would revolutionize craniofacial defect treatments. This dissertation demonstrated the ability to 
engineer bone, cartilage, and osteochondral tissue with native structure and physiologic function 
from a clinically favorable cell source, hMSC. The following study utilized a personalized 
bioreactor for the engineering of anatomically shaped oesteochondral grafts. The design of this 
bioreactor is suitable for clinical translation. The TMJ condyle-specific bioreactor was created as 
the first in a family of systems. The TMJ was chosen as the target graft of this study because of 
its complex shape, moderate size, mechanical loading properties, and the great need for this graft 
in craniofacial reconstructions. Although the bioreactor was specifically designed for the TMJ 
condyle, the flexibility of its design allows for extensions to numerous other grafts. 
RECONSTRUCTION OF THE HEAD AND FACE: RECENT ADVANCES AND CURRENT NEEDS 
Defects in the head and face regions due to trauma, tumor removal, or congenital abnormalities 
not only leave patients with reduced tissue structure and function, but also render them 
psychologically scarred. The burden of craniofacial injuries extends far beyond medical 
expenses, as these injuries often impair the patient’s social integration. Due to the complexity of 
craniofacial reconstructions [265][266], the currently available treatment options fall short of 
adequate care [267][268]. There is a pressing need for functional and esthetic restoration of a 
multitude of bones including TMJ, zygomatic arch, cranial, nose, temple, mandible, and orbital 
bone. The current market for craniofacial bone is estimated at $390 million for trauma alone, a 
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figure based on the overall trauma market of $3 billion in 2010, with facial trauma representing 
13% of all traumatic bone injuries [269]. 
Numerous bone-grafting options exist for head and face reconstruction, depending on the 
specifics of the defect and the patient’s clinical condition. Autologous bone implantation is 
widely adopted because of the superior osteogenic, osteoinductive, and osteoconductive 
properties of native bone [270]. Sources of autologous grafts determine their quality and 
functionality in the craniofacial complex. The membranous bone grafts, such as those harvested 
from cranium [271], are superior to endochondral bone grafts in terms of volume maintenance 
[272]. Highly vascularized grafts, such as vascularized bone flap from fibula or iliac bone [51], 
have the advantage of rapid incorporation into the host bone and vascular flow [270]. Finally, 
costcochondral grafts can repair composite defects of bone and fibrocartilage [50, 51]. 
Autologous grafts are considered a gold standard for head and face reconstruction due to their 
bioactivity, mechanical competence, and immediate cellular function. However, the restricted 
availability of harvestable bone, donor site morbidity, the lack of precision in carving delicate 
shapes of craniofacial bones, and differences in the structure and biomechanics of bones from 
different parts of the body call for alternative methods. 
Allografts and alloplastic substitutes provide an unlimited off-the-shelf supply of implants in a 
range of sizes and shapes. Bone allografts are osteoconductive and may also contain 
osteoinductive capability [273, 274]. For comparison, a demineralized bone matrix (DBM) 
exhibits significant osteoinductive behavior and imparts osteoconductivity to the collagen matrix 
[275]. However, the use of allografts is often associated with infection, disease transmission, and 
immunological rejection. Processing bone allografts into a demineralized bone matrix can 
significantly reduce these complications [274].  
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In contrast, alloplastic grafts are fabricated from synthetic materials, such as hydroxyapatite, 
calcium phosphates, polymers, plastics, and metals, and carry less burden of infection or immune 
rejection. Nonbiological grafts can also be designed to provide desired mechanical strength, size, 
and shape to meet specific implantation requirements. However, the osteoinductivity and 
osteoconductivity of alloplastic grafts are generally inferior to those exhibited by autologous or 
allogeneic bone grafts [270]. Also, the nonbiological nature of alloplastic grafts does not provide 
metabolic function, adaptation, and remodeling of bone (e.g., in response to mechanical loading 
and aging), all of which are critical for long-term function of implanted grafts.  
Existing grafting techniques offer a variety of tools to reconstruct head and face defects, with 
tolerable success. Nevertheless, disadvantages and complications of existing bone grafts inspire 
clinicians, scientists, and engineers to develop more effective bone treatment modalities. A major 
trend in this direction is the development of personalized bone grafts that are autologous in 
nature and have properties tailored to the patient and the specific clinical situation. 
The important criteria for developing functional grafts for head and face reconstruction include 
(i) superior bioactivity for successful graft incorporation, (ii) native-like graft shape and 
architecture for aesthetic purposes, and (iii) maintenance of tissue volume during and beyond the 
bone remodeling period. Patient-specific bone grafts can be designed to synergize the advantages 
of autologous and alloplastic grafts. A personalized graft (with respect to its shape, architecture, 
and immune compatibility) is readily accepted by the patient’s immune system and designed to 
match, with great precision, the structural and biomechanical features of the donor site to ensure 
full reconstruction of both esthetics and function. The availability of personalized human bone 
graft customized to the patient and the specific clinical condition would revolutionize the way we 
currently treat craniofacial defects. 
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Figure X-1: Key strategies for engineering personalized grafts. (i) Bioactive scaffolds with 
incorporation of bioactive molecules, designed to recruit the host cells, (ii) cell-seeded scaffolds, 
with or without additional bioactive factors, designed to foster rapid bone growth inside a 
scaffold providing structural and mechanical competence, and (iii) autologous bone grafts grown 
in vitro to various levels of maturity, designed to provide immediate function along with the 
capacity for integration with the adjacent tissues and blood supply. The similarity to native bone 
tissue increases from bioactive scaffolds to cell-seeded scaffolds and to preformed bone, whereas 
the readiness for clinical application decreases in this same order. 
ENGINEERING PERSONALIZED HUMAN GRAFTS 
A fundamental requirement for personalized craniofacial reconstruction is to fulfill the functional 
and aesthetic properties of native bone. This is achieved through fabrication of an anatomically 
shaped, functionally resilient graft that is able to integrate with the host bone, adjacent soft 
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tissues, and vascular supply. Due to the complex shapes and dynamic properties of the facial 
skeleton, in addition to patient defect variability, imaging-guided tissue engineering technologies 
are of great interest. Computer-assisted imaging and preoperative planning are increasingly used 
to predetermine the surgical location and to facilitate manufacturing of patient-specific implants. 
Rudman et al. summarized the innovations in computer- assisted reconstructive surgery, 
including anatomic considerations, implant materials available, technologies for preoperative 
planning, and the process of obtaining a patient-specific graft [276]. Clinical experience 
demonstrates that virtual planning, rapid prototype modeling, and stereotactic navigation for 
complex craniofacial defects can provide the reconstructive surgeon with innovative options for 
treating challenging and patient- specific reconstructions [277]. The use of computer-assisted 
imaging allows an exact fabrication of a personalized graft matching the aesthetic requirements 
of head and facial reconstructions. 
Three strategies of great interest for engineering personalized bone grafts rely on the use of (i) 
bioactive scaffolds, (ii) cell-seeded scaffolds, and (iii) autologous bone grafts grown in vitro 
(Fig.X-1). These three strategies result in different maturities of the implanted tissue (from 
scaffold alone, over immature cellular graft, to preformed bone) and the promptness for 
translation (with cell-free scaffolds being closer to clinical application than cellular or bone 
grafts). 
Option 1: Bioactive acellular scaffolds 
The first option for personalized bone reconstruction is biodegradable synthetic scaffolds with 
incorporated osteoinductive factors that can recruit the host cells and guide bone ingrowth. 
Ideally, bone healing responses to implantation of these scaffolds involve host inflammatory 
reaction, cell proliferation, migration, differentiation, revascularization, and new bone formation 
[270]. The biodegradation can progress through hydrolysis or osteoclastic resorption at rates 
allowing isomorphic replacement of scaffold material with new bone tissue. The bioactive 
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function should support all processes involved in bone tissue formation—vascularization, 
osteogenic differentiation, and prevention of scar formation. In addition, mechanical properties 
of the scaffold are important, especially for load bearing sites. Two techniques are being actively 
pursued for the design of bioactive scaffolds: (i) fabrication of hierarchical structures resembling 
those of the native tissue to provide mechanical support and direct cell migration and 
differentiation and (ii) incorporation of biomolecules to recruit cells and guide bone formation. 
Considerations for scaffold architecture include porous channels for cell migration, surface 
features for cell attachment, and mass-transport conduits for cell nutrient delivery. Due to the 
complexity of facial bones, an “ideal” scaffold would have a hierarchical porous structure to 
attain desired mechanical function and mass transport and would allow manufacturing of 
complex three-dimensional anatomical shapes [278]. Common methods for fabrication of 
anatomically shaped scaffolds include molding and machining [279, 280]. An example of highly 
anisotropic structure is the TMJ that contains vertical lamina of cancellous bone, with the matrix 
density decreasing from superior to inferior across the condyle [281, 282]. Another example is 
the zygomatic arch (cheek bone) that has a porous central region and a compact rim, with 
trabeculae arranged vertically and anteroposteriorly [283-286]. 
Recently, manufacturing techniques known as solid free-form fabrication (SFF) and rapid 
prototyping have been successfully used to fabricate complex scaffolds. SFF builds parts by 
selectively adding materials, layer-by-layer, as specified by a computer program [287]. Using 
this technique, scaffolds were fabricated to match the anisotropic structure of human mandibular 
condyle from polycaprolactone [278]. Optimizing architecture and scaffolding material for 
biocompatibility and osteoconductive properties would greatly improve the quality of tissue 
engineered human bone graft. 
Incorporation of biomolecules into alloplastic scaffolds could be utilized to recruit specific cell 
types to promote bone regeneration. With advances in scaffold fabrication and controlled release 
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of bioactive factors [288, 289], “smart” scaffolds are becoming available to provide both a 
structural template and the temporal control of osteoinductive factors. The utilization of growth 
factors, including transforming growth factor beta, bone morphogenetic proteins (BMP), 
fibroblast growth factors, insulin-like growth factors, and platelet-derived growth factor in the 
repair of bone have previously been reviewed [290]. Scaffolds releasing multiple factors in a 
timely fashion— for example, initial release of cytokines to recruit cell migration followed by 
the release of vasculogenic and osteogenic factors to direct bone formation—would be most 
effective for guiding bone regeneration. Cytokines, such as BMP-2, are currently being used 
commercially, whereas the more complex systems, such as multiple cytokines incorporation, are 
only being investigated in vitro. 
Option 2: Cell-seeded scaffolds 
Cellularized grafts, in general, provide better remodeling and integration with the host tissue than 
acellular scaffolds. Cell-seeded scaffolds combine the benefits of exogenous cells with the 
incorporation of bioactive molecules and the use of customized scaffolds. In order to prevent 
immunological response, the graft can be made using autologous materials. Harvesting 
osteoblasts from native tissue would cause donor site morbidity and is, therefore, not a method of 
choice. Instead, less invasive harvesting methods are preferred to obtain autologous cells from 
whole bone marrow (BM), adipose tissue or the platelet-rich plasma (PRP). Bone marrow is rich 
in biomolecules and cells responsible for normal maintenance of bone, including three types of 
stem cells: hematopoietic, mesenchymal, and vascular precursor cells. Autologous PRP is 
commonly used in clinical settings to treat injury and defects. PRP consists of concentrated 
platelets in a small volume of plasma extracted from whole blood. It comprises seven 
fundamental protein growth factors proven to be actively secreted by platelets to initiate wound 
healing and three blood proteins known to act as cell adhesion molecules for osteoconduction 
and synthesis of connective tissues and epithelial migration [291]. Both the bone marrow and 
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PRP can be harvested and seeded into anatomical shape scaffolds in a point-of-care setting 
immediately prior to implantation. Adult stem cells, particularly MSC, have also demonstrated 
high clinical potential in the application of personalized grafts for head and facial reconstructing. 
MSCs are the most extensively investigated and utilized therapeutic cells for bone regeneration. 
These cells have been successfully used in orthopedic cell-based reconstructive therapies [292]. 
However, the utilization of any type of adult stem cells in cellularized bone grafts requires 
isolation, purification, and in vitro expansion in order to obtain an adequate number of high-
quality stem cells. 
Immature cellularized grafts, obtained by seeding of scaffolds immediately prior to implantation, 
enhance osteogenesis in the site of bone defects through the signaling of biological factors and 
constituent cell populations. The enhancement in craniofacial reconstruction was investigated 
using various combinations of cellular and scaffolding materials in several autologous 
implantation models: BM in a scaffold [293], PRP in a scaffold [291], BMSC in a scaffold [294], 
and BMSC with PRP [295]. In general, grafts containing cells were superior to their respective 
no-cell controls, conclusively suggesting that implanted autologous cells contribute to the 
reconstruction process. Challenges for fabricating personalized immature cellular graft include 
obtaining sufficient amounts of cellular material, providing spatially uniform and rapid seeding 
of large anatomically shaped scaffolds, maintaining graft survival postimplantation, and 
controlling cells to undergo tissue-specific formation in vivo. 
Option 3: Customized autologous bone grafts 
Stem cell biology has advanced to the point that allows biologists and bioengineers to manipulate 
cells into specific tissue types and form in vitro skeletal tissues. Engineering clinically sized 
autologous bone grafts requires a large number of cells and advanced cultivation systems to 
provide adequate cell seeding of anatomically shaped scaffolds, sufficient nutrition to the cells 
within scaffolds, and regulatory signals for cell differentiation and functional assembly [77]. 
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Various technologies have been developed for engineering human bone grafts by utilizing 
scaffolds and bioreactors [77, 84, 85]. In a suitable environment and with adequate stimulation, 
stem cells differentiated into osteogenic cells, producing bone proteins and minerals [296, 297]. 
Notably, tissue engineered bone grafts were superior to scaffold alone and cell-seeded scaffold in 
terms of graft incorporation into the critical size mouse calvarial bone defects [225].  
Maintaining cellularity in large, anatomically shaped bone grafts in vitro can be a challenging 
task. Recently, Grayson et al. [78] reported that clinically sized, anatomically shaped, viable 
human bone grafts can be engineered in vitro using human mesenchymal stem cells and a 
“biomimetic” scaffold-bioreactor system. Human TMJ was selected as a model because of the 
tremendous clinical importance of TMJ and the challenges associated with reconstructing its 
complex shape and load-bearing function. Anatomically shaped scaffolds were generated from 
fully decellularized trabecular bone using digitized clinical images and seeded hMSCs. A novel 
bioreactor with a chamber in the exact shape of a human TMJ was designed for controllable 
perfusion throughout the engineered construct. By employing computer software to analyze fluid 
flow patterns, the medium perfusion was optimized to ensure nutrient transport within the 
forming tissue. 
After five weeks of cultivation, tissue growth was evidenced by the formation of confluent layers 
of lamellar bone (by scanning electron microscopy), markedly increased volume of mineralized 
matrix (by quantitative microcomputer tomography), and the formation of osteoids 
(histologically). For the first time in bone grafts of this size and complexity, cells were fully 
viable at a physiologic density, likely an important factor in graft function. The density and 
architecture of the bone matrix correlated with the intensity and pattern of the interstitial flow, as 
determined in experimental and modeling studies. This approach has the potential to overcome a 
critical hurdle—in vitro cultivation of viable bone grafts of complex geometries—and to provide 
patient-specific bone grafts for craniofacial and orthopedic reconstructions. 
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The potential of engineering autologous craniofacial grafts with precise anatomical shapes, 
internal architectures, and biomechanical properties matching the properties of native tissues is 
tremendous and requires further investigation on bench-top and in large animal studies. The 
technology could impact research in developmental biology (where high-fidelity tissue models 
can be used to study bone formation), as much as clinical translation (by providing large and 
viable anatomically shaped bone grafts for treating craniofacial or orthopedic defects). Current 
developments are nearing a point where such an approach could become clinically feasible for 
reconstruction of small- to moderate-sized bone defects. 
CLINICAL TRANSLATION OF ENGINEERED CRANIOFACIAL AUTOLOGOUS GRAFTS 
The availability of customized, living, engineered tissues would significantly enhance graft 
function, reduce surgical time, and eliminate issues with donor site morbidity by substituting the 
use of harvested autografts with engineered autologous grafts. Engineered autologous grafts 
(option 3), though less prompt in terms of clinical translation than bioactive scaffolds (option 1) 
and cellularized grafts (option 2), exhibit superior bioactivity for successful graft incorporation, 
the most important criteria for medical reconstruction. Recent years have brought significant 
advances in the synergistic utilization of stem cells and bioengineering for craniofacial 
reconstruction, and identified some of the remaining challenges in clinical translation. 
The ultimate goal of tissue engineering is to create native-like tissue grafts in vitro for 
therapeutic purposes. TMJ condyle is one of the most complex bones in the craniofacial skeleton 
in term of its load-bearing and osteochondral properties. Table X-1 summarizes the requirements 
and key findings obtained from the studies in this dissertation. The ideal grafts must be readily 
accepted by the body and exhibit native tissue function. Clinical knowledge has proven that the 
use of autologous tissue or cell sources would eliminate the medical complications caused by 
graft rejection; thus, autologous MSC are the most therapeutic-ready cell source. In addition to 
autologous property, essential aspects in the context of osteochondral tissue engineering are the 
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ability to form bone and cartilage tissue, and the ability to provide strong tissue interface. 
Mimicking physiologic structure, biological expression, and mechanical function would allow 
for graft incorporation and survival post implantation.  
Table X-1 Engineered osteochondral graft requirements and solutions 
Requirements Solutions  
Graft immunogenic 
suppression 
Autologous MSC isolated from bone marrow or fat 
Bone formation Regulating bone mineral and protein matrix deposition 
(Aim 1) 
Cartilage formation Directing articular cartilage formation with cell pellet 
compression technique (Aim 2) 
Bone-cartilage integration Supplying nutrient and factor through perfusion bioreactor 
(Aim 3) 
This dissertation has shown success in controlling tissue matrix assembly to form bone and 
articular cartilage structures from hMSC and in providing an adequate system to enhance bone-
cartilage integration. In Aim 1, bone architecture was engineered under the regulation of mineral 
and bone protein deposition. Further, articular cartilage was engineered by directing hMSC 
differentiation through mesenchymal condensation under the novel cell pellet compression 
technique (Aim 2). Finally, integration between bone and cartilage was enhanced with sufficient 
supply of culture media and biological factors with perfusion through bone region (Aim 3). 
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PERSONALIZED OSTEOCHONDRAL BIOREACTOR DESIGN CONSTRAINTS  
The accomplishments and key findings obtained in this dissertation provided understanding on 
the important features required for successful personalized osteochondral bioreactor design. 
Ideally, a complete bioreactor system should be capable of (i) supporting cell proliferation and 
differentiation throughout the complex-shaped multi-phase constructs, (ii) coordinating 
biological, physiological and mechanical stimuli, (iii) applying stimuli in a spatially and 
temporally controlled manner to provide lineage-specific stimulation within the cartilage and 
bone regions, and (iv) providing sufficient nutrient supply to all compartments of the graft. 
The design constraints for successful engineering of personalized osteochondral grafts are to 
allow for (i) manufacturing of anatomical grafts, (ii) cellular support, (ii) stimulation of bone 
development, (iv) regulation of articular cartilage formation, and (v) spatial control of tissue 
formation. Based on key findings in the recent studies, the tissue engineering techniques were 
developed to address these requirements (Table X-1). Anatomically-shaped scaffolds can be 
fabricated using SFF or 3D milling from computerized 3D program. Medium perfusion provides 
sufficient supply of nutrient to support cellularity in large constructs. To engineer osteochondral 
constructs from hMSC, undifferentiated cells must be seeded into the bi-phasic construct and 
spatially supplied with osteogenic and chondrogenic media in bone and cartilage region 
respectively. 
DESIGN OF PERSONALIZED OSTEOCHONDRAL BIOREACTOR  
A personalized osteochondral bioreactor was developed, which fulfills the previously mentioned 
designe constraints. Fig.X-2 shows the schematic of the system. The system consists of one 
culture chamber where the cellularized construct is located, and two reservoirs containing 
osteogenic and chondrogenic media. The two media are perfused into the chamber to provide 
nutrients and stimulating factors to the different region of the bi-phasic osteochondral construct. 
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The culture chamber consisted of five main components (Fig.X-3A): (i) scaffold, (ii) PDMS 
block, (iii,iv) two manifolds, and (v) case. To assemble the bioreactor, the scaffold is inserted 
into the PDMS block, which is specifically fabricated to match the construct anatomical shape. 
The PDMS block is then sandwiched between two polycarbonate fluid-routing manifolds, while 
a tubular enclosure slides over the assembly, providing a compressive force to tightly seal the 
components together (Fig.X-3B). The polycarbonate manifolds are designed with four ports for 
medium perfusion: two inlets and two outlets each for chondrogenic and osteogenic media 
(Ill.X-2). Chondrogenic media enters the chamber at the articular side of the manifolds and is 
perfused into the PDMS block on top of the articular surface of the condyle. Osteogenic media 
enters the chamber at the subchondral side and is perfused into the PDMS and through the bone 
scaffolds.  
 




Figure X-3 Culture chamber consists of (A) five main components assemble together (B). (C) 
Modeling of flow dynamics to determine channels size and location that provide homogenous 
flow. (D) Components to create PDMS block with pre-determined channels. 
Large anatomically shaped constructs require a well-controlled nutrient supply to support cell 
viability and stimulate tissue formation. For homogenous medium perfusion, channels within the 
PDMS block are sized according to the local scaffold thickness and are positioned to provide a 
near-uniform flow velocity throughout the scaffold of the bone region (Fig.X-3C). The sizes and 
placement of perfusion channels were determined by computational flow dynamics modeling to 
ensure the homogenous distribution of medium flow. Once the location and the size of channels 
to provide homogenous flow was determined, the mold to create PDMS block was created 
(Fig.X-3D). The positive TMJ shape mold and the outside casing containing the pre-determined 
holes for channels were 3D print. Multiple channels were inserted through the pre-determined 
holes of the outside casing into the TMJ shape mold. PDMS was poured into the empty space 




Figure X-4: Flow testing. The whole scaffolds turned green after 30 seconds of perfusing green 
dye solution confirming the homogeneity of media flow through the scaffolds. 
In comparison to a previously developed perfusion bioreactor for engineering anatomical bone 
graft which was successful in delivering sufficient factors through out complex cellularized bone 
constructs of small and moderate size [78], the new system offers several additional advantages. 
This new system allows for multi-phase tissue formation with spatially-controlled nutrient 
supplies, the most important requirement in engineering osteochondral and other complex 
constructs. A major drawback of the previously developed perfusion bioreactor was the inability 
to control the homogenous medium flow scheme, which resulted in a different cellular response 
and morphology across the volume of the constructs. The design was simplified by reducing the 
number of inlet/outlet ports while providing a more homogenous perfusion scheme through the 
porous scaffolds. The improvement in design allows for cultivation of constructs with any size 
and shape while sufficiently providing nutrient supply to the whole construct. The prototype of 
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the bioreactor was fabricated and tested (Fig.X-4). Within less than 30 seconds of introducing 
green dye solution, the anatomically shaped TMJ scaffold fully dyed indicating the effectiveness 
of the new perfusion bioreactor in supplying nutrients. In conclusions, this design addressed all 
the design constraints of a successful system for engineering personalized osteochondral grafts 
which are summarized in Table X-2.  
Table X-2 Personalized osteochondral bioreactor design constraints and solutions 
Design constraints Solutions  
Manufacture cellularized 
anatomical graft 
Fabricate and culture cell-seeded anatomically-shaped 
scaffold 
Support cellularity Provide homogenous media perfusion throughout the 
anatomically-shaped scaffolds 
Stimulate bone development Induce undifferentiated hMSC-seeded constructs with 
osteogenic media 
Regulate cartilage formation Induce undifferentiated hMSC layer with chondrogenic 
medium 
Spatially stimulate tissue 
formation 
Completely separate osteogenic and chondrogenic media 
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CHAPTER XI 
Feasibility, Efficacy, and Future Challenges of Engineered Autologous Grafts 
Tissue engineering offers promising alternative treatment modalities for regenerative medicine. 
The ability to create autograft-like constructs will have tremendous benefit clinically, socially, 
and economically. Thus far, the sophisticated process in generating engineered autologous grafts 
from stem cells limits the progress to laboratory bench and small animals. With advancement in 
stem cells biology and bioreactor systems, the ability to engineer autologous grafts with 
clinically relevant size has become possible. This chapter presents the feasibility in generating 
engineered autologous bone grafts in a pre-clinical set up and demonstrates the efficacy in 
implementing the engineered autologous grafts for treating craniofacial defect. 
CRANIOFACIAL RECONSTRUCTION WITH ENGINEERED AUTOLOGOUS GRAFTS 
Maxillofacial surgeons are faced with the challenge of reconstructing complex deformities that 
require functional and cosmetic aesthetic precision. Clinically-used grafts must be predictable, 
and shoud exactly matching the 3D form unique to every patient defect. The current standard of 
practice depends on lengthy procedures, secondary surgical sites, and immense resources, but, in 
many instances, still yields non-ideal results. With advancements in tissue engineering, we are 
increasingly able to produce autogenous bone grafts engineered in vitro through regulation of 
osteogenic differentiation and functional assembly of stem cells. Here we report our experience 
with custom-made bone grafts of the TMJ condyle and ramus with the use of autogenous adipose 
stem cells (ASCs) in a large-animal study (Yucatan minipig). The planned duration of the study 
is 6 months. Here, the mid-point analysis was reported in which 2 pigs from each implantation 




Figure XI-1: Surgical planning and RCU scaffold fabrication were conducted for each pig. Each 
pig was CT scanned (A) and the facial skeleton was 3D reconstructed (B). Left RCU was 
selected for reconstruction (C) and used as a template for scaffold fabrication from adult bovine 
trabecular knee bone block (D). 
Preparation of personalized TMJ scaffolds 
Yucatan minipigs were randomly divided into 3 groups: (i) condylectomy (n=2) as negative 
control (to verify that there is no spontaneous regrowth), (ii) scaffold implantation (n=6) as a cell 
control (to determine the relative contributions of the cells in performed bone), and (iii) 
engineered autogenous bone graft implantation (n=6). The process for fabricating anatomically-
shaped TMJ condyles for implantation was adapted from our previous work [78]. In brief, facial 
skeletons of each pig were CT-scanned and reconstructed in the form of 3D digital files (Fig.XI-
1A&B). Left ramus-condyle units (RCU) of 4 cm in width and 6 cm long were chosen for 
reconstruction (Fig.XI-1C). Anatomically-shaped scaffolds for each pig were fabricated from 
 124 
trabecular bone of adult bovine knees based on previously reported methods [78] (Fig.XI-1D). In 
brief, adult bovine knees were cut to remove cartilage and cortical bone to obtain large inner 
trabecular bone blocks. The blocks were lathed to obtain long cylinder of at least 5 cm in 
diameter and 8 cm long. The blocks were placed onto a 4-axis 3D milling machine and, based on 
the selected 3D construct RCU, the blocks were milled into the exact shape and size for each pig. 
The anatomical RCU grafts were washed and decellularized using the method previously 
described in Chapter VII. The scaffolds were autoclaved to obtain sterility for implantation. At 
this point, the sterile anatomical RCU grafts were ready for pig scaffold implantation. 
Engineered personalized autologous TMJ condyle grafts 
To engineer the autologous bone graft, the scaffolds were seeded with autologous ASCs isolated 
from subcutaneous fat of each pig, as previously described [298]. The cells were expanded in 
culture and 80 million cells were seeded into each pig-specific TMJ condyle scaffold. The newly 
designed personalized bioreactor, described in Chapter X, was modified in this experiment to 
investigate feasibility and efficacy of engineered autologous bone grafts for craniofacial bone 
reconstruction. The size of the bioreactor design was increased to allow for cultivation of the 
much larger pig TMJ and the design was modified to only support the cultivation of the bone 
region (Fig.XI-2A). Personalized PDMS blocks were fabricated using the method described in 
the previous chapter (Fig.XI-2B). Pig-specific scaffolds were seeded with autologous ASC 
within the personalized perfusion bioreactor setup. In brief, anatomical-shaped decellularized 
bone scaffolds were placed in personalized perfusion bioreactor. The cells were suspended in 40 
ml osteogenic media and injected into the bioreactor chamber until the suspension fully 
penetrated into the porous scaffolds (Fig.XI-2C). The bioreactors were placed in an incubator for 
2 hours prior to initiation of media perfusion to allow cell attachment. This technique resulted in 
~50% seeding efficiency. The grafts were cultured in osteogenic medium in specially designed 
perfusion bioreactors at 37°C for 3 weeks prior to implantation to allow for stem cell growth, 
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osteogenic differentiation, and bone matrix deposition (Fig.XI-2D). The perfusion velocity used 
was 40 μm/s for the first 3 days and increased to 400 μm/s for the rest of the cultivation period as 
this has shown to be the optimized velocity for culturing tissue engineered bone constructs [297].  
 
Figure XI-2: (A) Personalized perfusion bioreactor for engineering pig TMJ condyle graft. (B) 
Mold to create PDMS block with pre-determined channels, the main component to regulate 
homogenous perfusion. (C) Scaffold was filled with cell suspension after injection. (D) 
Bioreactors were connected to a pump and placed in 37°C humidified incubator for cultivation. 
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Graft implantation 
Grafts were transported from New York, NY to Baton Rouge, LA for implantation. During the 
transportation, the personalized perfusion bioreactor containing engineered autologous grafts 
were disconnected from the pump and placed in an insulated container with cold packs to reduce 
cell metabolism rate. The total disconnection time was approximately 12 hours. The bioreactor 
was reconnected to the pump upon arrival at the final destination and placed in an incubator at 
least overnight prior to implantation. Though we detected some evidence of cell detachment due 
to transportation, the implanted scaffolds contained of approximately 2.9 times more cells than 
the scaffolds immediately after seeding. 
 
Figure XI-3: Anatomical TMJ graft implantation. The anatomical grafts generated had the exact 
shape and size as the extracted RCU. (D) The graft was fixated with two titanium plates and (E) 
inserted and fixated onto the defect.  
Condylectomies to include a portion of the ramus were planned virtually and carried out under 
general anesthesia. The pigs selected for implantation were reconstructed using either scaffold 
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alone or engineered autologous bone graft. Bone grafts were successfully fabricated to contain 
the exact shape and size unique to each condyle (Fig.XI-3A-C). All grafts were rigidly fixated 
using 2.0 mm titanium miniplates (Fig.XI-3D&E).  
 
Figure XI-4: Regeneration of RCU in scaffold implantation (A-C) and engineered autologous 
graft implantation (D-F). CT images at 3 months showed graft resorption in scaffold 
implantation (A&B) while the engineered autologous graft implantation showed regeneration of 
RCU (D&E). Gross section of ramus showed fibrous ingrowth in scaffold implantation (C) at the 
implanted area (box) as opposed to bone regeneration in engineered autologous graft 
implantation.  
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Regeneration of ramus-condyle unit 
CT scans were conducted after surgery (day 0), at 6 weeks, 3 months, and 6 months (in 
progress). TMJ condyles were harvested after sacrifice and assessed for graft remodeling in 
terms of compactness, integration, and resorption. All pigs survived the surgery without 
complications. At 3 months, pigs with untreated condylectomies regenerated incomplete ramus-
condyle units (RCU). Pigs with scaffold implantation showed incomplete regeneration with 
significant scaffold resorption (Fig.XI-4 A-C). In contrast, pigs with autologous tissue 
engineered bone displayed regeneration as well as integration of the RCU (Fig.XI-4 D-F). The 
harvested condyles at 3 months demonstrated clear differences between the groups, with 
regeneration of a rigid and functional mandible in the engineered autologous bone graft group. 
The scaffold-only group failed to obtain comparable results, and healed with graft resorption and 
fibrous ingrowth. Based on the results of large animal model thus far, autologous tissue 
engineered bone is a promising treatment for facial bone reconstruction due to its ability to 
maintain tissue volume and enhance regeneration.  
WHAT HAS BEEN DONE AND WHAT NEEDS TO BE DONE 
The large animal study validated the feasibility in implementing the engineered autologous graft 
technology. The overall process represented the procedure that would be applied clinically. 
Anatomical scaffolds were fabricated to exactly match the defect to facilitate implantation and 
reconstruction. Autologous adult porcine stem cells were isolated and employed in order to 
prevent immune rejection. The cells were transported from medical facility to the laboratory and 
expanded, and the engineered autologous grafts were created within 5 weeks from the day of 
stem cells isolation. Furthermore, the grafts were successfully transported back to the medical 
facility for implantation with good cellularity, the key component responsible for engineered 
tissue function. As a result, the engineered autologous graft exhibited great efficacy in 
reconstructing craniofacial bone defect. 
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Optimizing and innovating systems to transport engineered grafts will likely increase cellular 
maintenance thus improving graft quality. Furthermore, understanding the essential biological 
signals and mechanisms for tissue regeneration would provide a thorough knowledge toward 
controlling stem cell differentiation. The techniques and systems established in this dissertation 
theoretically would allow for successful engineering and initial validation of osteochondral 
grafts. A more detailed validation in an animal study with larger group sizes is an obvious need. 
CONCLUSIONS 
The ability to generate native-like autologous grafts relies on the ability to regulate stem cells to 
produce native tissue matrix architecture by providing a suitable environment (physically, 
chemically, and biologically) and the right tools (bioreactor system). This dissertation 
successfully demonstrated the ability to control tissue matrix assembly by hMSCs cultured in 
scaffolds using advanced bioreactor systems towards the engineering of native-like bone, 
cartilage, and osteochondral grafts. By combining concepts and approaches of developmental 
biology and tissue engineering, bone, cartilage, and osteochondral constructs with physiological 
structures and functions were engineered in vitro. The feasibility and efficacy of implementing 
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